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Abstract  
 
Volumetric modulated arc therapy delivers highly conformal radiotherapy treatments 
to cancer patients in a continuous arc whilst dynamically varying the multi-leaf 
collimator (MLC) position, dose rate and rotational angular velocity. The present 
master’s thesis seeks to develop a better understanding of delivering treatment in this 
manner, ranging from progressive resolution inverse optimisation, class solutions, 
clinical application and the ability of dose calculation algorithms to model such a 
complex modality.      
 
A progressive resolution based class solution for inverse planning has been 
developed, outlining contouring, field set-up and optimisation. This class solution was 
then applied to 10 prostate patients and subjected to an inter-comparative planning 
study with static gantry intensity-modulated radiotherapy. The results of this 
justification study showed the presented class solution produces plans that are 
generally and directly comparable with previously published data. Following this 
result, the class solution was applied to a previously uninvestigated clinical site 
(treatment of prostate bed following radical prostatectomy) in an effort to solve 
persistent clinical problems involving target volumes and dose escalation. The results 
of this secondary study provisionally showed the feasibility of treating prostate beds 
with rotational intensity-modulated techniques whilst maintaining the integrity of the 
target volumes and escalating the delivered dose.  
 
The potential for improving the accuracy of the dose calculation analytic anisotropic 
algorithm for volumetric modulated plans was also investigated, through 
configuration of two independent algorithms containing beam data taken with either 
the linac jaws or MLCs defining the field. The two algorithms were inter-compared in 
virtual water phantoms and against physical verification measurements. The 
configuration process has shown to be sensitive to depth dose data but not beam 
profiles. Furthermore, the two algorithms show no significant difference and therefore 
it is recommended that beam be taken with the jaws defining the field. 
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Chapter 1 – Introduction   
 
1.1 Introduction to Radiotherapy 
 
Since the initial discovery of the x-ray by Wilhelm Röntgen over a century ago the 
applications of radiation have been wide, with arguably many of the most important in 
medical diagnostics and therapy. Major clinical and technological advancements have 
driven the field from a simple tool used to image the bones of one’s wife, to the 
successful therapy of deep malignant tumours with large – and dynamic – linear 
accelerators (linacs).  
 
Following this initial discovery, progress within the field was swift, with the term 
‘radioactivity’ coined by Madame Curie the year following. Her subsequent work, 
including the isolation of radium in 1898, was integral to this development. It was 
noticed early on, that exposure of radiation to superficial cancers caused them to 
regress, with anecdotal historical evidence suggesting that the first cancers were 
‘cured’ with radiation just four years [7] following Röntgen’s initial discovery in 
1895. Many of these early treatments would later prove to be palliative in nature due 
to normal tissue complications and the high rate or recurrence, as a result of the crude 
delivery techniques [8]. Following these initial disappointing results it was realised 
that higher energy radiations were required to adequately treat deeper disease, and by 
1913 Coolidge had developed an x-ray tube with peak energy of 140 kV, and by 1922 
this was further increased to 200 kV. The basis for modern radiotherapy fractionation 
can be traced back to as early as 1911 [8]. Claudius Regaud first demonstrated the 
benefit of fractionated treatment schemes with a series of experiments applied 
clinically to head and neck cancers, followed by cancer of the cervix [9], with 
improved treatment outcomes with multiple smaller daily fractions to the same 
treatment site.    
 
Higher energy radiotherapy was not realised until the implementation of the first 
megavoltage teletherapy machine in 1937 [1], coinciding with the move from 
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palliative to true curative treatments, as clinical knowledge grew and treatment 
became more reproducible and systematic [10]. This machine treated patients at St 
Bartholomew’s Hospital in London, up to an energy of 1 MV using dual 9.25 m long, 
500 kV x-ray generators [1]. The mid 1930s also saw the conceptual development of 
an electron accelerator using resonant microwave cavities, but was not clinically 
practical due to the low power levels of the then current microwave generators [1]. 
This impracticality was overcome due technological developments as a result of 
military radar research, related to World War II. Based on this design, the first 
medical linac (Figure 1.1) was installed for clinical use, treating the first patient on 
September the 7th 1953, at Hammersmith Hospital in London [1]. Other noteworthy 
developments in this early period included the installation of the first three linacs in 
Australia (1956-57), one soon after in New Zealand and the first Varian isocentric 
linac (6 MV) installed at the University of California, Los Angeles, Medical Centre in 
1962. 
 
 
Figure 1.1: Scale model of the first linac installed in Hammersmith Hospital, 1952. 
Reproduced from [1]. 
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The next major development in radiotherapy came with the invention of the computed 
tomography (CT) scanner by Sir Godfrey Hounsfield. First proposed in 1968, and 
acquiring the first clinical image on October 1st 1971 at Atkinson Morley’s Hospital, 
London (Figure 1.2), aiding in the diagnosis of a frontal lobe tumor that was later 
excised [2]. Conceptually, the CT scanner took digital radiographs using an x-ray 
generator-detector system at all angles around an object, and digitally reconstructed a 
three-dimensional (3D) dataset from the combined attenuation values. The 1970s also 
saw further refinements in linac design, to a point where modern linacs can easily 
trace their lineage. Technological advancements including improved vacuum pumps, 
bending magnets and wave guides meant that linacs were relatively stable, compact, 
reliable, fully isocentric, and capable of producing both photons and electrons [1]. 
 
 
Figure 1.2: The first clinical CT scan, performed at Atkinson Morley’s Hospital on 
October 1st 1971. Red arrow indicating left frontal lobe tumor. Reproduced from [2].   
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Clinical knowledge continued to grow in parallel with the above technological 
advancements. This fact in conjunction with advancements in other clinical methods 
for cancer treatment (surgery and chemotherapy), resulted in survival analysis for all 
cancer sites showing a significant increase in five year survival; from 39% in the 
1960s to 50% by the end of the 1970s [8]. Although this increase was promising, with 
a number as low as 50%, it was obvious that further advancements were still required.  
 
Modern radiotherapy is yet to experience a revolution in the technology it uses to 
deliver therapeutic doses of radiation, with the basic concepts of design and structure - 
formed in the 1970s - still underlying the construction of modern linacs [8]. However, 
as with any technology dependent technique, further refinement of the major 
components, coupled with the continual improvements in computing power (correctly 
predicted by Moore’s law [11]) have improved to a standard of performance that is 
essential for the delivery of modern conformal techniques [8].   
 
Until the introduction of CT imaging, treatment planning was done in a purely two-
dimensional (2D) manner. Radiation fields were placed with the aid of bony anatomy 
visualised on plane radiographs and were often simple rectangular shapes. The 
technology of CT imaging had since progressed to a point where 3D data sets of 
patient anatomy could be imaged and reconstructed in a matter of minutes, with a high 
level of resolution and contrast, and therefore could be used for not only diagnostic 
imaging but therapeutic treatment planning. Radiation fields could now be shaped to 
fit anatomical specific targets, resulting in what is now called 3D conformal 
radiotherapy (3DCRT).The advantage of this technique came with more conformal 
dose distributions, allowing higher doses to the tumor, with lower doses to normal 
tissues, improving clinical outcomes. Further developments in linac functionality 
included mounted imaging devises and multi-leaf collimators (MLCs), pioneering the 
way for image guided radiotherapy (IGRT) and intensity-modulated radiotherapy 
(IMRT) respectively. 
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1.2 Intensity-modulated Radiotherapy 
IMRT is considered (by some [12, 13]) as the most important development in 
radiotherapy treatment planning and delivery since the above mentioned integration of 
CT imaging [4]. The seminal IMRT paper was published in 1988 by Anders Brahme 
et. al. [3], suggesting that even more conformal dose distributions could be achieved 
through modulating the intensity not only between separate fields but within each 
field itself (Figure 1.3). This allows the intensity of radiation passing through 
sensitive normal structures to be reduced, and the intensity through target volumes 
increased [4]. Thus, allowing higher doses to be given to target structures with similar 
or reduced doses to normal tissue, and therefore, theoretically improve clinical 
outcomes. The implementation of this theoretical work was dependent on 
development of beam modifiers (MLCs) and the methods used to calculate the non-
intuitive beam apertures, through inverse planning techniques. No concise, universal 
definition of IMRT exists but many have been suggested, for example [4]: 
 
“IMRT is a radiation treatment technique with multiple beams in which at least some 
of the beams are intensity-modulated and intentionally deliver a non-uniform intensity 
to the target. The desired dose distribution in the target is achieved after 
superimposing such beams from different directions. The additional degrees of 
freedom are utilized to achieve a better target dose conformality and/or better sparing 
of critical structures” 
 
 
Figure 1.3: Original IMRT illustration from Brahme [3] indicating five intensity 
modulated beams and their corresponding intensity profiles. The hatched area 
indicated the target volume. The intensity profiles show a reduction in areas where the 
path covers mainly normal tissue and an increase when the path is mainly target.  
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The development of inverse planning algorithms has several major milestones. The 
concept of defining upper and lower structural constraints was first introduced in 1988 
[14], but Steve Webb was the first to realise that inverse planning for IMRT was an 
optimisation (minimising an objective or cost function) problem due to the fact that 
there was no exact solution [15]. This is a result of the physical constraints of 
radiation and the fact that it is impossible to produce negative dose intensities. 
Therefore, no set of modulated beams can deposit a prescription dose to the target and 
no dose to the surrounding normal tissues. Since there is no exact solution, the 
optimal solution will be the one that comes as close as possible to this unachievable 
solution, or in mathematical terms, the sum of the squared deviations between the 
delivered and prescription dose, which is to be minimised [4]. Many of the modern 
inverse planning algorithms are based on subsequent work by Bortfeld, published in 
1990 [16]. Bortfeld realised that the above problem with a quadratic objective 
function does not have local minimums, and therefore fast gradient decent methods 
can be used to find the optimal solution [4], greatly reducing optimisation times.  
 
Much of this early optimisation work was purely theoretical, with no knowledge of 
how the optimised, modulated beams would be physically produced. The use of 
various beam modifiers, such as metal compensators, were envisioned but this was 
impractical due the specificity of each patient, field and field segment [4]. This was 
overcome as MLCs (Figure 1.4) became commercially available in the early 1990s. 
Consisting of multiple individually driven tungsten leaves, MLCs were originally 
designed for beam shaping in 3DCRT, but would soon become invaluable in the 
delivery of IMRT treatments.  
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Figure 1.4: Multi-leaf collimator (MLC) with tungsten leaves producing a complex 
shape. MLCs that move dynamically throughout treatment are an essential component 
of IMRT treatment delivery. Reproduced from [4].  
 
The first publication outlining a feasible method for delivering arbitrary intensity 
profiles using an MLC that moved dynamically, in a unidirectional sweep throughout 
treatment, was published in 1992 [17]. Here, relatively large dynamic apertures are 
used with the field open to areas of high intensity for a larger fraction of time than 
areas of low intensity, hence producing a profile with varying modulation. This model 
was subsequently improved to include the finite acceleration and velocity of 
individual leaves, leaf transmission and penumbra affects, to form the basis for 
modern sliding window IMRT delivery [4]. A separate delivery method was 
developed independently and simultaneously [4], whereby each intensity profile is 
built up using a succession of discrete field segments each delivering a fraction of the 
total field fluence. This work was the basis for the modern step-and-shoot IMRT. 
Each intensity-modulated delivery technique has advantages and disadvantages, but 
the driving force for step-and-shoot being the fact that MLC movements are made 
while the beam is off and therefore the probability for an error in treatment may be 
reduced [4].   
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The use of medical imaging for patient position verification in radiotherapy has a long 
history, with the first reports of pre-treatment electronic portal imaging (EPI) dating 
back to 1958 [18]. Further advancements of these techniques have made imaging a 
useful tool in routine clinical patient set-up. The advent of IMRT has taken these tools 
from the useful to the essential. Modern linacs (Figure 1.5) now incorporate MV 
(EPIs) and on board kV imaging systems (including cone beam CT), to detect 
systematic or random set-up error, and guide field set up and patient positing in 
radiotherapy. The sharp dose gradients produced by intensity modulation increases the 
risk for a geographical miss. Therefore, imaging becomes essential for patient 
verification to ensure that the target is receiving the desired dose and normal tissues 
are not being over dosed [19]. IGRT also has the potential to reduce the target volume 
size and therefore further reduce the volume of normal tissue irradiated.  
 
 
 
 
Figure 1.5: IGRT and RapidArc capable Varian Trilogy iX. IGRT capabilities 
include MV (EPI) detector and kV source and detector. Reproduced from Varian 
Medical Systems, Inc., Palo Alto, CA, USA.    
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The first IMRT verification measurements were taken in 1994 by Bortfeld [20]. This 
verification was done for a prostate step-and-shoot IMRT plan with 225 segments, in 
an anthropomorphic pelvis phantom stacked with film. The delivery of this treatment 
took over three hours (mainly due to a cumbersome MLC) but produced surprisingly 
good agreement between planned and delivered dose. Following further work, the first 
clinical patient treated with inverse planned, MLC delivered IMRT was at the 
Memorial Sloan Kettering Cancer Centre, New York, in 1996 [21]. This treatment 
was done as an extension of the centers long standing dose escalation prostate study 
and conservatively gave a 9 Gy sliding window IMRT boost, on top of the previously 
treated 72 Gy 3DCRT plan. Early comparative planning study data presented the 
related dose volume histogram (DVH), showing a reduced rectal dose for the 
composite IMRT plan, compared with the standard 3D plan [21]. In concurrent 
development was an independent method of delivering intensity-modulated radiation, 
whereby fields are delivered through a rotational fan-beam in a similar fashion to a 
CT scanner, coined Tomotherapy by the seminal paper in 1993 [22]. The first clinical 
Tomotherapy treatment was in August of 2002 at the University of Wisconsin [23].      
 
Further development in modern oncology (across all disciplines) has continued the 
trend to improve the prognosis for all cancers [8]. As illustrated in figure 1.6, deaths 
directly attributed to cancer are significantly below what was extrapolated in 1990, in 
the United States [5]. The overall death rate for men decreasing by 19.2% and 11.4% 
for women, between 1990 and 2005. Despite this, in 2004 cancer was still the leading 
cause of death worldwide, being attributed to 13% of all deaths [24], and in 2009 
cancer caused more deaths in developed countries than heart disease in the under 85 
year old age bracket [5]. These world wide statistics are reflected in local regions, 
with cancer ranked as the second leading cause of death in New Zealand [25] and 
Australia [26, 27]. In conjunction with this, cancer incidence is predicted to continue 
to rise  [24, 27]. As a result, further development in the field is required, both 
clinically and technologically, with the goal of improving therapeutic ratios and 
curing more people.       
 
                                                                    10 
 
Figure 1.6: Total number of avoided cancer deaths in the United States. The blue line 
represents the total number of reported cancer deaths per year. The red line represents 
the expected number of deaths if mortality rates had not improved from 1990 through 
to 2005. Reproduced from [5]. 
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1.3 Volumetric-modulated Arc Therapy 
 
The two major disadvantages of IMRT when compared with conventional 3DCRT 
include an increase in both the time and monitor units required for treatment. These 
two disadvantages result in decreased productivity, increased costs, and potentially an 
increased risk of secondary cancers due scatter and leakage radiation [28, 29]. An 
attempt to address both of these issues comes in the form of rotational based IMRT or 
volumetric-modulated arc therapy (VMAT). The seminal paper for this technique was 
published in 2008 by Karl Otto [6] but work on rotational IMRT dates back to the 
inception of more traditional intensity modulated techniques. Namely, the early 
development of intensity-modulated arc therapy (IMAT) was published by Cedric Yu 
in 1995 [30]. This method proposed a sliding window type IMRT, delivered over 
several continuous arcs.  
 
Further IMAT based developments have since been made [31] but wide spread 
clinical implementation has been sparse due to several limiting factors. Firstly, in 
order for the treatment to be delivered throughout constant gantry rotation, the 
changes in MLC leaf position must be restricted between consecutive gantry 
positions. This has been overcome through the use of several superimposed arcs [30, 
32, 33] but this increases treatment time to the point where it is comparable with 
conventional IMRT. Secondly, inverse optimisation of the dynamic treatment is 
simulated through a coarse sampling of gantry angles and beam apertures, often 
resulting in unacceptable dosimetric differences between the planned and delivered 
treatment [6, 33].  
 
The recent work by Otto [6] builds on the original concepts outlined by Yu [30] but 
introduced two further dynamic variables on top of the dynamic gantry and MLCs, 
namely dose rate and gantry angular velocity [6]. This initial work also outlines the 
mathematical grounding for an efficient inverse planning algorithm used to produce 
this complex plan and treatment delivery [6], and overcome the above limitations of 
IMAT. This algorithm is based on the previously published concept of direct aperture 
optimisation [32], rather than more conventional inverse optimisation of beam 
fluence, followed by MLC sequencing. This aperture based algorithm varies the MLC 
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position and monitor unit (MU) weight then evaluates the change based on a quadratic 
cost function and the dose-volume constraints that define it [6].  
 
The revolutionary step that VMAT takes is the method used to sample the continuous 
dynamic arc by a finite set of static fields, or control points. Initially, a relatively 
coarse sample of the full arc is taken (Figure 1.7(a)) with a control point at the start 
and end of the arc, and evenly spaced points between. After a certain number of 
iterations (MLC and/or MU weight changes) further control points are added (Figure 
1.7(b)-(c)) between each existing point. The MLC positions and MU weights for these 
new points are interpolated and calculated from neighboring points respectively [6]. 
This process is repeated (Figure 1.7(d)) until the finite sample gives an accurate 
representation of the dynamic arc [6]. Sampling the arc in this fashion allows the 
optimiser to converge towards an optimal solution in a practical time frame, whilst 
still giving a dosimtrically accurate representation of the full dynamic arc.   
 
 
Figure 1.7: Illustration of VMAT progressive control point sampling. (a) Shows the 
initial coarse distribution of static control points, (b) the introduction of the first 
interpolated point, (c) the full sample in the second progressive level and (d) the 
addition of further points. Reproduced from [6].    
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Since this initial publication, there has been three clinical implementations of VMAT, 
each with subtle differences in both optimisation and delivery; RapidArcTM (Varian 
Medical Systems, Inc., Palo Alto, CA, USA), Elekta VMATTM (Elekta, Inc., 
Stockholm, Sweden) and Phillips SmartArcTM (Phillips, Inc., Andover, MA, USA). At 
the time of writing volumetric-modulated are still in the early stages of development, 
with the RapidArc (RA) system seeing the largest uptake in both the clinic and 
literature [34]. The first planning study comparing 3DCRT, conventional IMRT and 
VMAT was published later in the same calendar year [35], comparing prostate 
delivery for 3DCRT, IMRT and VMAT. VMAT plans were calculated using a 
predecessor algorithm that would eventually become Varian’s RA, and were 
optimised using both constant and variable dose rates throughout gantry rotation. The 
results of this paper show that the VMAT plans had comparable conformity, 
homogeneity, and organ sparing to conventional IMRT. A further improvement in 
organ sparing with variable dose rate VMAT was also observed. As expected, both 
intensity modulated techniques had greatly improved organ sparing when compared 
with 3DCRT. One of the techniques driving advantages was also upheld with an 
average reduction in MUs of 40%, when compared with static gantry IMRT. 
Although treatment times were not directly addressed, a reduction in treatment time 
can be inferred as a consequence of the large reduction in MUs.   
 
Subsequent planning studies have extended this proof of principal to other treatment 
sites, including; prostate with seminal vesicles (SV) and pelvic nodes [36-38], head 
and neck [39, 40], malignant gliomas [41, 42], anal canal [43], breast [44], cervix 
[45], multiple brain metastases [46, 47] and peadiatric cancers [48]. To generalise 
these studies, the results have shown that VMAT produces comparable or even 
slightly improved dose distributions, with a significant reduction in both MUs and 
treatment time over a wide range of clinical sites [34]. The above studies are all based 
around RA optimisation and delivery, but similar results have been published for both 
Elekta VMAT [49] and Phillips SmartArc [50]. The theoretical advantages of 
volumetric-modulated techniques are the subject of ongoing debate within the 
literature [51-53].   
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1.4 Motivation and Outline of Work 
Arc-based radiotherapy is a complex technique that has been made possible due to 
recent developments in both linac hardware and optimisation algorithms. Although 
the technique is still in its infancy, the proposed advantages are already well 
established. The reduction in treatment time gives immediate advantages within the 
clinic, increasing patient throughput or allowing more time for image guided or 
adaptive treatments. The long term follow up of a large cohort of patients is required 
to determine if the reduction in MUs does in fact result in less secondary cancers. 
Volumetric-modulated based techniques still have a long way to grow until maturity 
is reached, with much still unknown about the inner workings and user consequence 
of the progressive optimiser, accuracy of the associated dose calculation algorithms, 
and areas of unexplored clinical application. The present work attempts to address the 
following questions: 
 
v How does the PRO differ from static gantry inverse planning and what is the 
result for the end user? 
v Can planning class solutions improve and standardise the planning process?  
v To produce the optimum plan, are user interactions required throughout 
optimisation? 
v What further clinical issues can be solved with conformal RA techniques? 
v When calculation dose from volumetric modulated deliveries, can the 
accuracy of the analytic anisotropic algorithm be improved by applying more 
appropriate configuration beam data?   
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Chapter 2 – RapidArc Planning Strategy  
 
2.1 Introduction 
 
Living up to it’s namesake, interest in and the clinical uptake of rotational forms of 
IMRT has been rapid since the seminal publication by Otto [6].  This uptake has come 
on the back of a  variety of planning related studies [35-39, 41-44, 46-48, 54-59] 
comparing 3DCRT, static gantry IMRT, rotational IMRT and sometimes 
Tomotherapy or proton therapy [37, 38, 48, 55], for various clinical sites (including 
prostate [35-38]). The increasing maturity of the technique is such that it has even 
been described in review [34] along with several institutions publishing experience 
and data from their first 12 months of clinical treatments [60, 61]. In general, these 
studies have shown rotational IMRT to be at least comparable with static gantry 
IMRT (both IMRT techniques make improvements over standard 3DCRT) while 
many show an improved level of conformity, sparing of critical structures, and a 
slightly reduced level of homogeneity in the target volume. These studies have 
justified this rapid clinical adoption by providing evidence in favour for the major 
selling points of rotational techniques, by reducing both treatment time (TT) and 
monitor units (MUs) significantly, when compared with other intensity modulated 
techniques.  
 
Although the clinical advantages of rotational techniques seem to be establishing 
themselves, a systematic process providing a turnkey solution for the inverse planning 
process is yet to be established. As a result, there is a strong correlation between the 
experience of the planner and the resulting plan quality. Therefore, reproducing this 
planning study data in the clinic can be a non-trivial undertaking. Rotational IMRT 
planning is performed through inverse planning techniques in a similar vein to that of 
static gantry IMRT but is further complicated due to the increased number of dynamic 
variables involved during delivery. Varian’s solution (based on [6]) to this further 
complexity is the introduction of a new resolution based optimisation algorithm to aid 
in the inverse planning process. The aim of this current work is to provide a robust 
strategy or class solution [62], which streamlines the planning process, produces 
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clinically acceptable plans in the majority of cases and is generally and directly 
consistent with previously published planning study data. 
 
An IMRT class solution has been previously defined by Mott et. al.[62] as:  
 
“…as a set of IMRT planning parameters (beam arrangements, dose limits and 
penalties) that can be applied to every patient” 
 
In the same fashion, this strategy will concentrate on RapidArc (RA) plans produced 
using the complementary planning software and the progressive resolution optimiser 
(PRO) for intermediate and high risk prostate patients, with a simultaneous integrated 
boost (SIB). The strategy will outline a systematic and streamlined workflow diagram 
and will cover; initial contouring and field set up, recommended starting objectives 
and required user interactions to be made throughout optimisation. This will be 
followed by a comparative planning study with standard static gantry IMRT, but will 
not be used as a justification for rotational techniques in general - as previously 
published - but instead for the methods used to produce the RA plans themselves. The 
results of this study will then be compared with to previously published data.  
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2.2 Methods 
 
Prostate cancer is the most frequently diagnosed cancer in men globally [24] and in 
local regions [25-27]. The following strategy is intended for the use of planning SIB 
RA plans for patients with intermediate and high risk prostate carcinoma with at least 
one phase including the SVs. This empirical strategy has been devised through 
extensive planning experience and modifications made to the many planning 
parameters involved across a range of patients, both adopting time proven static 
gantry IMRT inverse planning techniques and devising new RA specific techniques. 
In the following, the application of this strategy, which is divided into pre-
optimisation, optimisation and post-optimisation is described in general terms (2.2.1 
and figure 2.3) before it is applied to a specific prostate planning protocol (2.2.2), 
namely the Conventional or Hypofractionated High Dose Intensity-Modulated 
Radiotherapy for Prostate Cancer (CHHiP) trial protocol [63]. All planning was done 
in the Eclipse treatment planning system (TPS), version 8.5.  
 
2.2.1 Planning Strategy  
2.2.1.1 Pre-optimisation 
Contouring 
The first step of the planning process is the contouring. In addition to standard 
contours, such as the body, planning target volumes (PTV) and organs at risk (OAR), 
further structures are created to aid in the inverse planning process. This approach is 
in analogy to the use of complementary contours used for IMRT planning to improve 
spatial targeting of dose and is an essential step for this RA based planning strategy. 
Henceforth, these additional contours are referred to as virtual contours, but others 
may refer to them as auxiliary contours. These structures are produced through a 
combination of automated cropping tools built into the Eclipse TPS.  Examples are 
shown in Figure 2.1. In general, a virtual contour is created for any areas of overlap 
between PTV and OAR (Fig. 2.2a) and, if multiple dose levels exist within the target 
(e.g. prostate and seminal vesicles + margin → PTV1, prostate + margin → PTV2 and 
prostate → PTV3) (Fig. 2.2b). The virtual OAR structures allow for improved sparing 
                                                                    19 
of the associated OAR while not giving conflicting optimisation inputs. The PTV 
rings are necessary due to the fact that all PTVs occupy the same physical space and 
therefore non-conflicting objectives can be applied to each individually to reduce hot 
areas and improve homogeneity in the more superficial PTV areas.  
 
    
  
Figure 2.1: Virtual contours, as indicated by arrows. Image showing all three PTVs 
and two virtual structures (a). The two virtual structures represent the OAR (bladder 
and rectum) minus the largest volume PTV, plus an extra margin of 3mm. Illustration 
of two virtual PTV structures (PTV1 minus PTV2 (cyan) and PTV2 minus PTV3 
(green)) (b). 
 
  
(b) 
(a) 
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Field set up 
Once all the contours have been created a single arc field is set with a collimator 
rotation of 45° [64]. All RA plans require some degree of collimator rotation as to 
reduce the cumulative effects of tongue and groove leakage throughout gantry 
rotation, and to allow spatial modulation in the transverse plane. A collimator angle of 
45° has been chosen as it gives the maximum level of modulation in the transverse 
plane and has been shown by other authors to be the optimal angle for prostate 
simulated geometries [64]. The jaws are set to be open to the largest PTV throughout 
the entirety of the gantry rotation, with an extra margin of approximately 10 mm. 
Although not employed here, the above two parameters may then be automatically 
optimised in Eclipse version 8.6 and above. The arc is set to run from 179° through to 
181° in a counter clock-wise (CCW) direction or from 181° through to 179° in a 
clock-wise (CW) direction and the energy of the irradiating beam is 6MV. Although 
the target volume is deep, the fact that radiation is entering the patient from all angles, 
a beam energy of 6MV is adequate to produce acceptable dose coverage, without the 
increased neutron dose that will result from higher energy beams [65]. Other energies 
such as 10MV are not currently available in the Wellington Blood and Cancer Centre 
(WBCC) for planning or delivery, and are therefore not considered. The above field 
set up allows the optimisation algorithm the largest range of parameters, so that the 
chance of the best plan being produced is maximised.     
 
Progressive resolution optimiser 
RA optimisation and calculation in the Eclipse TPS utilises two identical algorithms 
to that of standard IMRT: the dose-volume optimiser (DVO) and anisotropic 
analytical algorithm (AAA). In brief, the DVO is an algorithm used to sample the 
dose distribution throughout optimisation. Points within investigated structures are 
sampled in a quasi-random nature and the dose calculated using the relatively fast 
multi-resolution dose calculation (MRDC) algorithm [66, 67]. The calculated dose is 
not stored but is used to calculate the current DVH and evaluate dose objectives. The 
AAA is the full dose calculation algorithm implemented post-optimisation, improving 
on accuracy when compared with the MRDC, at the cost of computational resource 
[66, 67]. The AAA is the topic of study in chapter 4.  
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The new - and unique - algorithm introduced specifically for RA is the progressive 
resolution optimiser (PRO) [6], as introduced in 1.3. Throughout optimisation the 
PRO makes iterative changes to the dynamic delivery variables (MLC, dose rate and 
gantry angular velocity) iteratively, in an effort to find the global minimum of the 
following objective function [6, 67]: 
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Where j is the current iteration, di is the dose at the ith point within a structure, p is the 
prescribed dose, wj is the multiplicative priority, and ξj is set to 1 if the objective is 
violated and zero if it is met [6, 67]. The global minimum (optimum solution) to this 
equation is found when the derivative is set to zero. The state of this function is 
assessed at the end of each iteration (based on the dose calculated by the MRDC), 
before further aperture based changes are applied. A real time graphical representation 
of this function is presented throughout optimisation, the gradient of which can 
indicate when user interactions are required (as referred to in 2.2.1.2).  
 
These iterations are separated into five independent resolution levels, as introduced in 
figure 1.7. The first resolution level represents the full arc by 10 control points 
(essentially static fields). This number of control points is then doubled plus one for 
each successive resolution level, with the final arc being represented by up to 177 
control points (Fig. 2.2 (a)-(e)). As each new control point is added, the dynamic 
variables are interpolated and calculated based on the two neighbouring and already 
existing points. The nature of this process means that the lower resolution levels are 
flexible to optimisation objective change but give a poor representation of the full arc, 
while the higher levels are less flexible but give a much more accurate representation 
of the full dynamic arc. What the introduction of this new algorithm means from a 
planning perspective will be outlined in the planning strategy below.  
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Figure 2.2: Figures (a) through (e) give a graphical representation of optimisation 
resolution levels 1 through 5, respectively.  Each level illustrates the control point 
distribution in relation the patient data set. 
 
Pre-optimisation dose objectives  
The inverse planning process is aided through the definition of optimisation planning 
objectives. These can be either upper or lower objectives that define the input data for 
optimisation penalty functions. Each objective corresponds to a point in the dose-
volume data space. Upper objectives give a maximum limit to the corresponding 
(a) 
(e) 
(d) 
(b) 
(c) 
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DVH whilst lower objectives give a minimum. Each objective has an assigned priority 
related to the penalty function input, acting in a multiplicative fashion. The normal 
tissue objective (NTO) is a set of input parameters that defines how dose falls off 
outside a defined PTV, and can be used to reduce hot spots in normal tissue and 
produce a sharp dose fall off outside target volumes. This function is mathematically 
defined as follows [68]: 
 
start
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where r = distance from the target border, rstart = starting fall-off point, f0 = start dose 
(%), f∞ = end dose (%) and k = fall off. An empirical set of these parameters, 
maximising organ sparing when only the NTO is applied throughout optimisation, is 
as follows; rstart = 0.2 cm, f0 = 103%, f∞ = 60%, k = 0.13, with a priority (P) of 150.  
 
The number of MUs required to deliver the sum of any given control point 
combination is directly related to the size of the corresponding MLC apertures. 
Furthermore, small MLC apertures may be associated with dosimetric errors between 
AAA calculated and deliverable dose (see chapter 4). Therefore, it is important that 
the maximum number of MUs is constrained throughout optimisation, as to uphold 
the advantages of RA in general and improve dosimetric accuracy, by increasing the 
average beam aperture size. The strength of this objective should be high (100) but 
may vary depending on clinical site (an example is given in the planning comparison).  
 
The planning strategy utilises a set of dose objectives that are set prior to the initiation 
of optimisation. A set of three objectives are assigned for each PTV, one lower and 
two upper objectives. The lower objective corresponds to 100% of the PTV volume 
and approximately 98% of the prescribed dose and the first upper objective, 0% 
volume and 105% of the largest prescribed PTV dose. Each of these objectives 
initially has a low priority (P = 50). The third objective is an upper objective with 
identical values to the above lower objective, except that it has a priority of zero. As 
alluded to earlier, the NTO needs a defined starting local, rstart. This position is the 
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PTV upper objective with the lowest corresponding dose. This third objective, 
henceforth referred to as the ‘butterfly objective’ (due to the fact that an upper and 
lower objective set at the same dose-volume point resembles a butterfly) is this 
starting point for the NTO. The priority of zero ensures that it has no effect on the 
penalty function output. In general, experience has shown that plans employing the 
NTO without a butterfly objective have a reduced level of PTV homogeneity, 
conformity and a higher maximum point dose, when compared to those that do 
include a butterfly objective.   
 
An upper objective for each OAR is defined so as to push any relative hot spots away 
from any OAR-PTV overlap areas. These objectives are set at the dose-volume point 
corresponding to 0% of the structure volume and 98% of the prescribed dose, with P = 
100. An upper objective for each of the virtual PTVs created to exclude overlap with 
other PTVs is also assigned. These objectives should have a volume of 0% and a dose 
half way between the two PTV prescribed doses and have a priority of P = 150. 
 
At this point, it is useful to add a variety of ‘ghost’ objectives. These objectives will 
be solely used as a visual aid for the planner and will have a priority of zero, and 
therefore not directly contribute to the optimisation. They may directly correspond to 
the planning protocol OAR dose constraints (as below) or any other user defined 
DVH points of interest. Once confidence in the above strategy is established, a 
planning protocol can be set within Eclipse to further automate and streamline the 
planning approach. 
2.2.1.2 Optimisation 
As previously stated, the lower optimisation resolution levels are sensitive to change 
but give a coarse representation of the final arc, where the reverse is true for the 
higher levels. As a consequence, it is important that appropriate MLC apertures are 
defined early in the optimisation process, as control points added further through the 
optimisation process will be interpolated from these initial apertures. This is achieved 
through reserving lower levels (1-3) for sparing of critical structures while PTV 
coverage is concentrated on during the later stages (4-5). This is reflected through the 
relative priorities of the corresponding structures. Once optimisation has been 
initialised, it is first allowed to stabilise to what is achievable through the initial 
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starting objectives and the NTO. Following this, OAR sparing is improved upon 
through the addition of several upper objectives added to the associated virtual OAR 
structures. Further objectives are not added directly to the OAR structures themselves 
as to eliminate conflicts of objectives in areas of overlap. In saying this, improved 
sparing of the virtual OAR will have an associated sparing of the OAR itself, due to 
the spatial link shared by the two structures. Highly critical structures (e.g. rectum) 
have assigned priorities of P = 125 while other less critical structures (e.g. bladder) 
have a lower priority of P = 50. These objectives are initially placed just below the 
corresponding DVH but are refined over the first three resolution levels to improve 
OAR sparing well within any user defined (ghost) constraints, using the gradient of 
the objective function values as a guide (pull DVH further when the corresponding 
DVH is less that -0.5). It is expected that PTV coverage throughout these resolution 
levels will be relatively poor, with sometimes sharp sigmoidal shapes, hot volumes 
and even larger cold volumes, but will show improvements throughout. In saying this, 
it is important that the PTVs’ DVHs at least cross through the upper and lower 
objective threshold. If this is not the case then there may be an issue with the defined 
objectives (including a conflict with dose prescription) or jaw positions.  
 
Once the optimisation reaches level four, the priority of the PTV objectives are 
increased to P = 200 (excluding the butterfly constraint that should be frozen at zero). 
In general, all other objectives and their associated priorities are frozen from this 
point, through to the completion of the optimisation process. Throughout the final two 
resolution levels the ability of the optimiser to meet the PTV objectives will improve. 
This will be at the cost of reduced OAR sparing but will be of minimal effect. If the 
virtual OARs’ DVHs move significantly from the objectives as they were at the end 
of level three, then they can be relaxed slightly as to give the optimiser a higher 
concentration on PTV coverage. Any PTV lower objective should be strictly met 
towards the end of level five. The priorities of the PTV objectives are increased in 
iterations of 50 (up to P = 400), at points when the gradient of the PTV objective 
functions drops below -0.5. Increasing the priorities in this fashion often results in an 
objective function that resembles an increasing sawtooth function. The collective PTV 
upper objectives do not need to be strictly met but should not be far off achieving the 
105% dose-volume point. It is not of high importance that any virtual PTV structures 
be strictly met and may be hidden from resolution level one. The optimisation is only 
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allowed to come to completion if the total objective function gradient is close to zero 
and the above guidelines are met. If this is not the case, the optimisation must be 
paused and PTV priorities increased further, until the above requirements are met.   
2.2.1.3 Post-optimisation 
Following optimisation, dose calculation is done using the optimised MU value and 
the AAA dose calculation algorithm with a dose grid size of 2.5 mm. The dose 
distribution is then evaluated and the DVHs examined for the plans ability to meet 
any dose constraints. If target volume coverage does not meet ICRU 83 criteria, there 
may be a need to re-normalise the whole plan by adjusting the plan normalisation 
value, usually by no more than 1-2%.   
2.2.2 Planning Study 
The following comparative planning study serves a two-fold purpose. Firstly, it 
provides a practical example of the above SIB RA planning strategy, implementing 
the CHHiP protocol. It secondly serves as an inter-comparison of the produced RA 
plans to static gantry IMRT plans, as a justification for the methodology used to create 
the RA plans. The study compares RA and IMRT plans produced for 10 randomly 
selected high and intermediate risk (as defined by the CHHiP protocol; clinical stages: 
T1b/c, T2a/b/c or T3a, and with PSA + ((Gleason score - 6)*10)>15), previously 
treated patients with prostate carcinoma at the WBCC. The comparison with 3DCRT 
has been omitted due to the results of previously published studies [35-38] and the 
difficulty of comparing SIB and sequential boost plans.  
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Figure 2.3: Summary of planning strategy, represented as a work flow diagram.  
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2.2.2.1 Planning Method 
All RA and IMRT plans were produced to comply with the control arm of the CHHiP 
protocol, and optimised using Eclipse V8.5, on a single PC housing a quad core 
2.5GHz processor. For both types of plans, dose calculation was done with the aid of 
the distribution calculation framework (DCF), whereby the computational workload 
was shared by eight networked PCs that were identical to that used for optimisation. 
The CHHiP protocol comes from a current prostate hypofractionation trial out of the 
United Kingdom [63]. The control arm of this trial gives up to 74 Gy to three separate 
PTVs using a SIB in 2 Gy daily fractions.  
 
All RA plans used in the study were planned as per the above strategy. Comparative 
sliding window IMRT plans consisted of five separate fields of gantry angles 0°, 45°, 
100°, 260° and 315°. These beam angles are in line with the local protocol that 
consistently produces plans of comparable quality to published class solutions [69]. 
The energy of these fields was 6MV and an identical NTO as above, was employed. A 
high priority was initially given to the target structures and once PTV coverage was 
sufficient, virtual organ objectives (P = 125) were added to spare the associated OAR 
as much as possible, without compromising the PTV coverage. See table 2.1 for a 
summary of IMRT starting objectives and priorities.  
 
As per the CHHiP protocol, the gross tumour volume (GTV) is defined as the prostate 
only, the clinical target volume (CTV) 1 as the prostate and seminal vesicles with a 5 
mm margin, CTV2 as the prostate plus a 5 mm margin and CTV3 as the prostate only. 
All PTVs (1-3) add an extra 5 mm to the corresponding CTV, except that for PTV2 
and PTV3 the margin in the posterior region (towards the rectum) is reduced to nil. 
PTVs one through three have prescribed 2 Gy equivalent doses of  54, 70 and 74 Gy 
respectively. See table 2.2 for a summary of contouring and prescribed doses.  
 
 
 
 
 
 
                                                                    29 
 
Structure Objective Volume (%) Dose (Gy) Priority Type 
PTV1 
Upper 0 77.0 250 PTV Upper 
Lower 100 59.2 300 PTV Lower 
PTV2 
Upper 0 77.0 200 PTV Upper 
Lower 100 71.0 300 PTV Lower 
PTV3 
Upper 0 77.0 200 PTV Upper 
Lower 100 74.0 300 PTV Lower 
Rectum Upper 0 73.0 100 OAR 
Bladder Upper 0 73.0 100 OAR 
 
Table 2.1: IMRT starting objectives. Butterfly and ghost objectives omitted. 
 
Structure 
Structure 
grown 
from 
Margin in all 
directions/posterior 
(mm) 
Prescribed 
dose (Gy) 
2 Gy 
equivalent  
Minimum 
isodose 
coverage 
(%) 
PTV1 
Prostate + 
SV 
10/10 59.2 54 76 
PTV2 Prostate 10/5 71 70 91 
PTV3 Prostate 5/0 74 74 95 
 
Table 2.2: Summary of CHHiP trial contouring and dose prescription. SV = seminal 
vesicles 
 
Normal tissues structures include the rectum, bladder, femoral heads (FHs) and the 
body (all defined as solid structures). The rectum is contoured from the anus 
superiorly through to the recto-sigmoid junction. The bladder is contoured in full from 
base to dome (any randomly selected patient deemed to have insufficient bladder 
filling (<140cc) was rejected from the study (n = 1)). All CHHiP dose constraints are 
replicated as ghost constraints in table 2.3. 
                                                                    30 
 
 
Structure Objective Volume (%) Dose (Gy) Priority Type 
PTV1 
Upper 100 57.7 0 Butterfly 
Upper 0 77.0 50 PTV upper 
Lower 100 57.7 50 PTV lower 
PTV2 
Upper 100 69.2 0 Butterfly 
Upper 0 77.0 50 PTV upper 
Lower 100 69.2 50 PTV lower 
PTV3 
Upper 100 73.0 0 Butterfly 
Upper 0 77.0 50 PTV upper 
Lower 100 73.0 50 PTV lower 
Rectum 
Upper 0 73.0 100 OAR 
Upper 80 30.0 0 Ghost 
Upper 70 40.0 0 Ghost 
Upper 60 50.0 0 Ghost 
Upper 50 60.0 0 Ghost 
Upper 30 65.0 0 Ghost 
Upper 15 70.0 0 Ghost 
Upper 3 74.0 0 Ghost 
Bladder 
Upper 0 73.0 100 OAR 
Upper 50 50.0 0 Ghost 
Upper 25 60.0 0 Ghost 
Upper 5 74.0 0 Ghost 
FH Upper 50 50.0 0 Ghost 
 
Table 2.3: RapidArc starting objectives. Butterfly and ghost objectives included.  
 
2.2.2.2 Evaluation Tools 
All statistical analysis was done using a one sided paired t test with values deemed to 
be statistically different if p ≤ 0.05. Estimated RA treatment times were calculated by 
dividing the arc length (358°) by the average gantry rotation rate, taken from the 
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Eclipse TPS output. Estimated IMRT treatment times were calculated through the 
sum of multiple factors; the time to deliver the beam (total MU/dose rate), the time to 
rotate through the range of field angles while travelling at 360°/min and an extra 
factor that accounts for the amount of time for mode up, data transfer of the MLC 
delivery files, error in the estimated rotation time and the operator deliver time. This 
method was devised by Oliver et. al. [55] and the time allocated for the above 
mentioned extra factor, equals 19.1 ± 2.2 seconds, per field. The quality of PTV3 
coverage was evaluated through the statistical comparison of the V95, D95, CI, HI, Dmax 
and Dmean, where V95 is calculated as the percentage of PTV3 receiving 95% of the 
target dose (or 70.3 Gy), the D95 is defined as the dose to 95% of PTV3 and the 
modified conformity index (CI95) defined as follows [70]: 
 
2
91
95
PTVV
V
CI =  (3) 
where V91 is the 91% isodose volume (equivalent to 95% of the prescribed dose to 
PTV2) and VPTV2 is the volume of PTV2. The conformity index gives an indication as 
to how conformal the minimum (95% as per ICRU) prescribed dose is to PTV2. CI95 
values closer to 1 indicate a higher level of conformity with any values outside the 
range of 0.9-1.5 deemed clinically unacceptable [70]. Due to the PTV geometries and 
dose gradients involved, the CI95 of PTV2 is the only index that gives an accurate 
indication of the overall conformity of the plan. The homogeneity index (HI) is 
defined as follows: 
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where D5% is the dose to 5% of PTV3, D95% is the dose to 95% of PTV3 and Dmean is 
the mean PTV3 dose. HI values closer to 100% indicate more homogeneous dose 
coverage within the target volume. The ability of the two treatment modalities to 
spare critical structures was assessed through dosimetric end points that correspond to 
the CHHiP protocol dose constraints, maximum and mean dose along with OAR 
equivalent uniform doses (EUD). The EUD is defined as the uniform dose that will 
produce the equivalent radiobiological effect as the organ specific non-uniform dose 
distribution. This value is mathematically defined as [71]:  
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where N is the number of voxels within the investigated structure, Di represents the 
dose to each individual voxel within the structure and a is an organ (or tumour, see 
chapter 4) specific dose volume parameter (a = 8.3 for rectum and a = 2 for bladder 
[35]).  
 
RA spreads low doses of radiation to larger areas of normal tissue and correlations 
between the induction of secondary malignancies and the volume of peripheral normal 
tissue receiving low doses of radiation have been reported [72]. Although this is not 
the concentration of the paper, volume of tissue receiving low doses (> 2 and 5 Gy) of 
radiation are also reported. 
 
2.2.3 User Interaction 
To further scrutinise the hypothesis that applying IMRT like class solutions to the RA 
planning process does not produce optimal plans and that user interaction is required 
(as presented above), all 10 patients were retrospectively re-planned with a single 
planning template set at the start of optimisation and the PRO allowed to run without 
user interaction. This template contained identical objectives to those found in table 
2.2, except that all PTV priorities were increased to 300. A set of five upper 
objectives were also added to the virtual organs at risk that correlate to the average 
values achieved in the previous RA plans, with a priority of 125. As a measure of the 
differences in the two sets of plans, the PTV Dmean, Dmax, HI and CI95, along with all 
rectal dose-volume points were then compared. 
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2.3 Results 
Justification for the outlined planning strategy is provided by the results of the 
comparative planning study as presented. The 10 patient mean PTV3 (Fig. 2.4 (c), 
rectum, bladder and left femoral head volumes were 94 ± 57 (standard deviation), 48 
± 11, 300 ± 120 and 182 ± 31 cm3 respectively. A summary of plan and target 
coverage parameters is found in table 2.4 and mean target and OAR DVHs in figures 
2.4 and 2.5 respectively. Representative dose distributions can be found in figure 2.6 
and example control point beams eye view (BEV) in figure 2.7. Consistent with 
previously published data and the driving force for rotational techniques, the MU and 
TT is significantly reduced for RA compared with static gantry IMRT. The V95, D95 
and Dmean all show no significant difference. The conformity of the RA plans is 
improved on average over IMRT although the maximum dose and homogeneity is 
slightly worse. Detailed analysis of PTV1 (Fig. 2.4 (a)) and PTV2 (Fig. 2.4 (b)) is not 
considered here but all 10 RA and IMRT plans comply with the CHHiP protocol 
requirements.  
 
 
RA IMRT 
Significance 
Average Std dev Average Std dev 
MU 541.0 21.1 805.7 81.9 RA<IMRT 
TT (s) 65.0 0.1 243.2 11.6 RA<IMRT 
V95 (%) 99.8 0.3 99.9 0.3 NS 
D95 (Gy) 71.6 0.3 71.7 0.4 NS 
CI95 1.08 0.08 1.17 0.08 RA<IMRT 
HI (%) 95.8 0.2 96.3 0.6 RA<IMRT 
Dmax (Gy) 76.4 0.6 75.6 0.5 RA<IMRT 
Dmean (Gy) 73.0 0.4 73.2 0.3 NS 
 
Table 2.4: Summary of planning study PTV3 analysis.  
                  Std dev = absolute standard deviation, NS = not significant 
                                                                    34 
 
 
 
Figure 2.4: Mean DVH for all 10 patients showing PTV1-3 (a)-(c), for RA and static 
gantry IMRT. 
 
(b) 
(a) 
(c) 
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Figure 2.5: Mean DVH rectum (a) and bladder (b), comparing RA with static gantry 
IMRT.  
 
Analysis of the three main OARs (rectum (Fig. 2.5 (a), bladder (Fig. 2.5 (b)) and the 
femoral heads) can be found in table 2.5. The RA plans spared the rectum better than 
IMRT over the whole range of dosimetric end points. The high volume end points 
(V80%-V30%) all showed a statistical difference while the low volume end points (V15% 
and V3%) do not. Although the maximal dose point is larger for the RA plans, the 
mean dose and EUD is still significantly lower. Analysis of the bladder shows 
improvements for RA although all of the investigated parameters were deemed 
statistically insignificant. The single dosimetric end point (V50%), mean and maximum 
dose of the (representative) left femoral head were all significantly improved for the 
RA plans when compared with the IMRT plans. 
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The average volume of normal tissue (body minus largest PTV) receiving more than 2 
and 5 Gy for RA is 8200 ± 1300 and 5650 ± 990 cm3 respectively. These values were 
on average lower for IMRT (7728 ± 1343 and 5320 ± 891 cm3), although both 
differences were not deemed significant. 
 
 
RA IMRT 
Significance 
Average Std dev Average Std dev 
Rectum 
V3% 68.7 2.4 68.8 2.3 NS 
V15% 59.1 3.0 60.3 2.8 NS 
V30% 47.2 5.4 52.8 4.4 RA<IMRT 
V50% 32.2 5.2 38.1 4.3 RA<IMRT 
V60% 27.5 4.7 32.3 4.3 RA<IMRT 
V70% 23.6 4.3 29.4 6.0 RA<IMRT 
V80% 19.8 3.8 24.0 3.4 RA<IMRT 
Dmax 73.9 0.9 72.7 0.8 RA>IMRT 
Dmean 36.2 3.8 39.7 3.1 RA<IMRT 
EUD 40.6 3.1 43.7 2.7 RA<IMRT 
Bladder 
V5% 65.9 9.1 68.2 5.2 NS 
V25% 37.4 17.5 42.8 19.2 NS 
V50% 18.7 11.8 22.1 14.1 NS 
Dmax 75.3 0.7 74.8 0.8 NS 
Dmean 25.7 10.0 27.5 10.8 NS 
EUD 52.8 4.6 54.0 4.6 NS 
FH 
V50% 18.1 6.3 23.9 9.9 RA<IMRT 
Dmax 39.8 5.4 47.4 1.8 RA<IMRT 
Dmean 18.3 4.0 22.2 6.2 RA<IMRT 
 
Table 2.5: Summary of planning study OAR analysis. 
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Figure 2.6: Representative sagittal dose distribution. RA (left) and five field IMRT 
(right). The dose colour wash runs from 40 through to 78.28 Gy. 
 
 
 
 
 
 
 
 
 
Figure 2.7: BEV control point examples taken from a single plan. Contours include 
the PTV and rectum.  
(a) (b) 
(d) (c) 
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When comparing the plans with and without user interactions, comparable PTV 
coverage was observed (Dmean and Dmax, CI95 and HI) whilst the quality of OAR 
sparing was reduced. The mean rectal dose-volume points were lower across the range 
of points measured, significantly so for the V50% point, as was the mean dose.  
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2.4 Discussion 
 
An empirical planning strategy has been developed and implemented in an effort to 
streamline, standardise and improve the overall plan quality resulting from the RA 
inverse planning process. This process has both familiar and foreign aspects with 
regard to static gantry IMRT. The introduction of a resolution based optimiser means 
that solely employing standard IMRT class solutions and strategies does not produce 
the optimal plan. This is mainly due to the fact that RA planning uses a multi-step 
optimising process. It is paramount to understand this process, in order to know when 
and how to apply appropriate planning based parameters and to guide the optimiser in 
the desired direction. The development of new RA specific strategies is important to 
ensure consistency amongst plans and to streamline the planning process in general, 
whist producing clinically acceptable plans for a wide variety of patient anatomies. To 
the author’s knowledge there is currently no published approach to class like solutions 
for RA planning and it is believed that development of these solutions will help 
departments reduce the time it takes to develop their own planning strategies when 
transferring from an existing static gantry IMRT program, or establishing a new 
dynamic IMRT program.  
 
Application of the above strategy to 10 prostate patients has shown that all plans not 
only comply with the acceptance requirements of the planning protocol but are 
generally in line with previously published RA, prostate planning study data [35-38]. 
A direct comparison with published data is still required as evidence that both 
techniques are not off-set from published data. A summary of target and OAR 
comparisons can be found in table 2.6 and 2.7 respectively. Direct comparisons can be 
difficult due to variations in patients, target definitions and even dose prescriptions. 
With this in mind, the author believes that the presented justification planning study is 
not only generally but also directly comparable to previously published data. The 
comparison with static gantry IMRT is limited due to the fact that a 5-field technique 
was implemented. The observed differences in OAR sparing between the two 
techniques may be reduced or even removed with a more sophisticated 7 or 9-field 
IMRT technique, although this would increase both the MUs and TT even further. 
With the above strategy and the empirical set of parameters presented, the mean RA 
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optimisation time was 15.0 ± 1.3 minutes, a justifiable increase compared to the static 
gantry optimisation time of 8.0 ± 0.6 minutes, when the reduction in MUs and TT is 
considered. 
 
 Planning study RA data Published RA data 
MU 541.0 454.2 35, 477 61 
CI95 1.08 1.12 
35 
HI 95.8 93.8 35, 93.8 61 
Dmax 76.4 78.5 
35 
Dmean 73.0 75.0 
35, 74.0 61 
 
Table 2.6: Plan and target volume comparison with published data. References 
indicated as superscript. 
 
 Planning study RA data Published RA data 
Rectum 
Dmean 36.2 40.2 36, 40.3 61 
EUD 53.1 50.0 35 
Bladder 
Dmean 25.7 43.3 36, 44.5 61 
EUD 32.6 32.1 35 
FH Dmean 18.3 19.4 61 
 
Table 2.7: OAR comparison with published data. References indicated as superscript.                                                        
 
The results of the plan comparison with and without user interactions is further 
evidence to the point that interactions are required to (1) assign the optimum virtual 
OAR objectives, dependent on patient specific anatomy and (2) define appropriate 
MLC apertures in the lower resolution levels. Further to this point, the average virtual 
OAR constraints used for the re-planned optimisation were based on values that had 
already proven successful for this small group of patients, and therefore it can be 
envisioned that applying these values to a wider range of patient anatomies may 
produce results with even more dramatic advantages. 
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Although the data is not shown, further investigations revealed that the addition of a 
second full arc further improves OAR sparing but the improvement was deemed 
unnecessary when the associated increasing in both MU and TT is considered. Plans 
with two full arcs are investigated further in chapter 3. The above RA planning 
strategy has also been successfully trialled on a similar yet distinct disease site where 
the PTV wraps around an OAR (thyroid bed and spinal cord respectively), and even 
more complex treatment sites such as head & neck. Whilst the details go beyond the 
scope of this work, initial findings indicate that the virtual contouring, NTO, butterfly 
objective and optimisation user interactions can be transferred as presented here. 
However, more work is required to be able to determine the optimal number of arcs, 
collimator angle, jaw size, MU objective and avoidance sectors. 
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2.5 Concluding Remarks 
The theoretical advantages of rotational techniques are well established but the 
detailed methods used to achieve these results – in the form of class solutions or 
otherwise – are yet to be published. In an attempt to supplement the literature, it has 
been shown that using the outlined field set up, starting objectives and optimisation 
strategy, prostate RA plans can be produced in a systematic manner to produce plans 
that are not only clinically acceptable but are generally and directly in line with 
previously published data. The slight increase in optimisation time of the PRO based 
inverse planning (compared with conventional inverse planning techniques) seems 
justified when other clinical advantages of RA are considered. Future iterations of the 
Eclipse TPS may also reduce this planning time gap. The MU and estimated TT are 
significantly reduced when compared with IMRT, whilst maintaining comparable 
target volume coverage and a slight improvement in conformity. RA OAR sparing is 
also shown to improve, although this may be reduced through comparisons to more 
sophisticated static gantry IMRT techniques. The presented planning strategy has 
been shown to work for the CHHiP protocol, but it can be easily modified and 
implemented to suit the specific requirements of other radiotherapy departments, in an 
effort to treat patients with high and intermediate risk carcinoma of the prostate in a 
highly conformal and time efficient manner.  
 
Extensive RA planning study data has been published for a range of clinical sites, and 
now a streamlined planning strategy has been formulated to compliment these studies. 
A clinical site that is yet to be investigated (related to but independent of the prostate 
study presented above) is treatment of the prostate bed in the post operative setting. 
This treatment site provides many of its own challenges and problems, some of which 
may benefit from the implementation of the presented RA planning strategy. The 
feasibility of this application is the focus of the subsequent chapter. 
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Chapter 3 – Prostate Bed Feasibility and 
Dose Escalation Study.   
 
3.1 Introduction 
The focus of chapter 2 was to develop a RA planning strategy whereas chapter 3 
switches tact to focus on the implementation of this strategy to an existing – and 
persistent – clinical problem within the WBCC, and is therefore more clinical in 
nature. The use of prostate bed radiotherapy as adjuvant therapy in men with adverse 
risk factors following radical prostatectomy, or in the salvage setting, offers a 
potentially curative treatment after an unsuccessful radical prostatectomy. In the 
adjuvant setting recent prospective randomised clinical trials have demonstrated 
significant improvements in both progression free and overall survival [73-76]. In the 
salvage setting, with either a rising prostate specific antigen (PSA) post surgery or a 
persistently elevated PSA following surgery, there have been no prospective 
randomised controlled trials investigating its use. However, numerous retrospective 
studies of salvage radiotherapy have demonstrated its efficacy. Furthermore, this data 
has been supported in both a multi-institutional pooled data analysis [77] and a 
comprehensive review of published studies [78]. 
 
Assuming that the residual tumour burden is much smaller than is the case with 
radical irradiation, modest doses of radiotherapy have generally been employed in 
post prostatectomy radiotherapy. In randomised clinical trials of adjuvant 
radiotherapy, patients were irradiated to doses of 60-64 Gy using 3DCRT and severe 
toxicity was unusual. For example, in the European Organisation for Research and 
Treatment of Cancer (EORTC) study at 5 years following treatment the cumulative 
incidence of grade 3 toxicity was 4.2% in the adjuvant arm and 2.6% in the 
observation arm (p = 0.073). However, the cumulative incidence of any grade of 
toxicity was significantly higher in the adjuvant arm compared to observation (64.9% 
versus 54.3%; p = 0.05) [76]. In the Southwest Oncology Group (SWOG) trial, 
although graded toxicity was not reported, rates of complications known to be related 
to treatment were also more common in the adjuvant radiotherapy arm (23.8% versus 
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11.9%; p = 0.002) [73]. 
 
At the dose levels used in both the SWOG and EORTC trials approximately 25% of 
patients will develop biochemical failure within 5 years. Moreover, in this group of 
patients local failure was the predominant site of relapse, suggesting that more 
aggressive local treatment might improve both biochemical control and survival.  
Although there is a considerable amount of data to support dose escalation for radical 
radiotherapy for localised prostate cancer [79-82], there is less data in the 
postoperative setting. Several small retrospective studies suggest that a dose response 
effect is seen with both adjuvant and salvage radiotherapy [83-86] and is supported by 
tumour control probability (TCP) modelling [87]. 
 
Following prostatectomy, the whole surgical bed may harbour microscopic disease 
and is therefore at risk of subsequent relapse [88, 89]. A number of consensus 
guidelines for target volume definition have been developed, based upon known 
patterns of recurrence [68, 90-92]. In these guidelines the posterior extent of the CTV 
often extends caudally either up to or behind the anterior edge of the rectal wall. With 
volumetric expansion to produce a PTV, this commonly creates a concave target 
volume that wraps around the rectum. Clinically, target volumes of this nature are 
difficult to treat effectively without significant rectal irradiation using simple 3DCRT. 
Compounding this problem is the fact that target volumes can show large inter-
fraction motion due the variability in OAR filling in close proximity [93]. As a result, 
the integrity of the PTV is often compromised as to reduce the dose to the rectum. 
However, IMRT techniques can produce isodose distributions with concave shapes, 
and therefore allow for a reduction in rectal irradiation [94-96] and may provide 
solutions to these issues.    
 
Fixed gantry IMRT has been extensively investigated as a primary treatment modality 
for prostate cancer [97-103], but there is less data on its use in the postoperative 
setting [104-106]. However, the limited clinical data available suggests a favourable 
toxicity profile in comparison to historical controls treated with 3DCRT and has been 
shown to allow for significant dose escalation. As an alternative form of IMRT, 
VMAT techniques similarly improves the conformity of radiotherapy [6, 34, 35], as 
presented in chapter 2. Rotational forms of IMRT are yet to be investigated in the 
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post-prostatectomy setting, and therefore in this planning study it has been 
retrospectively studied in a cohort of patients - previously treated with 3DCRT - in 
order to assess its ability to reduce rectal irradiation, whilst maintaining the integrity 
of the target volume and potentially allow for escalation of dose.  
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3.2 Patients and Methods 
3.2.1 Patient Cohort  
Data from ten consecutive patients who had previously undergone 3DCRT following 
radical prostatectomy at the WBCC were selected for the study.  
3.2.2 Treatment Planning  
All patients were prepared for simulation according to WBCC protocols as to ensure a 
constant bladder volume and an empty rectum. Patients were then CT scanned at 1.5 
mm slices in the supine position. A single clinician defined the CTV (see figure 3.1 
for examples of CTV and PTV definition) which comprised the whole prostatectomy 
surgical bed according to the consensus guidelines of the Australian and New Zealand 
radiation oncology Genito-Urinary group [68]. In brief, the inferior border of the CTV 
was defined as 6 mm inferior of the vesicourethral anastomosis (defined as the first 
slice below which urine was visible in the bladder), extended superiorly to include the 
seminal vesicle bed and laterally to the medial border of the levator ani muscle or the 
obturator internus. From the inferior border of the CTV to 3 cm superiorly the anterior 
border of the CTV was the posterior aspect of the symphysis pubis, and more 
superiorly included the posterior 1.5 cm of the bladder. In order to limit the amount of 
rectal irradiation the posterior extent of the CTV allowed a minimum 2 cm margin 
from the posterior extent of the CTV to the posterior rectal wall. The CTV included 
all non-vascular tumour bed clips wherever possible. The optimal CTV expansion 
during the original 3DCRT based treatment was 1 cm in all directions, reducing to 0.5 
cm in the posterior direction where it was not possible to meet the rectal dose 
constraints.  In some cases, reducing the posterior expansion to 0.5 cm still did not 
allow the rectal dose constraints to be met and clinical judgement was used on a 
patient-by-patient basis to manually reduce this posterior border further. For the 
purposes of the planning study two separate PTVs were defined but only one is used 
for any single treatment plan. PTV1cm is a 1cm CTV → PTV geometric expansion and 
PTVtreat is a 1cm CTV → PTV expansion, except in the posterior border where 0.5 cm 
was implemented, followed by a further reduction based on the clinician’s judgment.  
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Figure 3.1: Target volume definition indicating CTV, PTVTreat and PTV1cm 
 
The planning data set consists of 40 treatment plans (summary in table 3.1), with each 
patient in the cohort having four individual plans. All 3DCRT plans consist of three 
(anterior-posterior, left and right lateral) 18 MV beams with MLCs conforming to the 
PTV and enhanced dynamic wedges (EDWs) on the lateral fields. Plan normalisation 
was achieved through a single representative ICRU 50 point within the target volume. 
Two separate plans were produced with a conformal technique, the first plan (3D1cm) 
having PTV1cm as the primary target, and the second (3Dtreat), PTVTreat. Both of the 
above plans were prescribed 64 Gy in 32 fractions.  
 
All RA plans were optimised based on an previously published planning strategy 
[107], as presented in chapter 2. Modifications were made to this strategy as to reflect 
the planning goals of the treatment site in question. Doses to the rectum are often 
pushed very close to the planning dose constraints (D60% < 40 Gy and D40% < 60 Gy) 
[68] and therefore an additional 6 MV CCW arc was added, along with removing any 
restriction on the number of MUs. These modifications allow for higher degrees of 
modulation and therefore organ sparing. The resulting plans were globally normalised 
such that the D50% equalled the prescribed dose. A deviation of 0.5% from this point 
was allowed, as to meet other planning constraints. Again, two RA plans were 
produced for each patient but both have PTV1cm as the primary target volume. The 
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difference between the two plans comes in the prescribed dose, the first (RA64) having 
an identical prescription as the 3DCRT plans above, and the second (RA70), escalation 
this dose to 70 Gy in 35 fractions. 
 
Plan Technique Prescription (Gy) PTV volume 
3D1cm 3DCRT 64 PTV1cm 
3DTreat 3DCRT 64 PTVTreat 
RA64 RA 64 PTV1cm 
RA70 RA 70 PTV1cm 
 
Table 3.1: Summary of treatment plan data set       
3.2.3 Evaluation Tools  
A range of planning evaluation tools were implemented to inter-compare the four 
distinct sets of treatment plans to assess the techniques ability to treat the target 
volume, and spare critical normal structures. Dosimetric verification tools have also 
been used to assess the techniques ability to physically deliver the planned dose 
distribution. Acceptance criteria have been assigned for all of these parameters, a 
summary of which can be found in column 2 of table 3.2. Many of these evaluation 
tools have been used in previous chapters but are reproduced here for completeness.    
 
The dose-volume parameters were reported to assess PTV coverage, along with the 
conformity and homogeneity indices. DXX% represents the dose to XX of the target 
volume and is reported for the 98, 50 and 2% volumes. The conformity index (CI95) 
was calculated as a ratio of the 95% isodose line to the volume of the plan PTV [70]: 
 
PTVV
V
CI %9595 =  (6) 
Previously published studies [34, 35] have shown RA to be more conformal than 
3DCRT and therefore more strict CI95 constraints are assigned to RA plans than 
3DCRT. The homogeneity index (HI) was defined as follows: 
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where D5% and D95% are the doses to 5 and 95% of the PTV respectively, and Dmean is 
the mean PTV dose. HI values closer to 100% indicate a more homogeneous 
distribution of dose within the target volume. The number of MUs required for each 
plan is also reported.  
 
The ability of the treatment plans to spare the rectum was assessed through two dose-
volume points, the mean (Rmean) and maximum (Rmax) doses, and the EUD. The two 
dose volume points correspond to the two rectal constraints suggested by Sidhom et. 
al. [68], RYY%, where YY is equal to either 40 or 60% of the rectal volume. As 
presented in chapter 2, the EUD is defined as the uniform dose that will produce the 
equivalent radiobiological effect as the organ specific non-uniform dose distribution, 
and is a useful tool when inter-comparing plans with differing dose prescriptions 
and/or steep dose gradients. The generalised EUD formalism is defined as:  
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where N is the number of voxels within the investigated structure, Di represents the 
dose to each individual voxel within the structure, and a is an organ specific dose 
volume parameter. For the organ in question, it has been suggested that this organ 
specific parameter is equal to 8.3 [35, 108]. 
 
To assess the feasibility of delivering the highly modulated RA70 plans, patient 
specific verification measurements were done using the diode based ArcCHECKTM 
device (Sun Nuclear, Melbourne, FL) [109, 110]. This novel verification tool consists 
of 1386, 0.8 x 0.8mm diodes, helically distributed in a cylindrical Perspex phantom 
with dimensions of 26.6 cm diameter and 32.4 cm long. The diodes have a spatial 
resolution of 1cm in the axial and rotational axes. All 10 RA70 plans were transferred 
to a CT image of the phantom and re-calculated. These plans were then delivered to 
the phantom on a Varian Trilogy iX. Gamma comparisons were made between the 
TPS calculated and measured dose for gamma-index acceptance criteria of 3% dose-
difference and 3mm distance to agreement (DTA). Given this criteria we set a 90% 
pass rate for all points over a 10% dose threshold.  
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Verification measurements of this nature are novel and therefore comparable 
published data does not currently exist, although Iftimia et. al. [111] assessed RA 
verification for the corresponding 2D device, MapCHECK (Sun Nuclear, Melbourne, 
FL) 2D diode array. Reported MapCHECK gamma indexes (3%/3mm, threshold of 
10%) are in the range of 89.1-99.1%, with a mean of 94.4%. Although these methods 
are not directly comparable, the results are consistent with the constraints imposed 
above.  
 
Statistical comparisons of the above evaluation parameters were assessed using a one 
sided paired t-test, and deemed statistically significant when p-values were ≤ 0.05. 
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3.3 Results 
An example dose distribution for each planning technique can be found in figure 3.2. 
The volume of PTV1cm was significantly larger than PTVTreat with mean values of 
306.6 ± 70.4 and 275.8 ± 60.1  cm3, respectively. A summary of all plan acceptance 
criteria can be found in table 3.2, noting that not all comparative permutations have 
been calculated, with obvious or nonsensical comparisons omitted. Average and 
statistical comparisons of the above planning parameters can be found in table 3.3, 
whilst average DVH data for the PTV and rectum can be found in figure 3.3(a) and 
(b) respectively. A representative ArcCHECK dose difference comparison can be 
found in figure 3.4, indicating the measurements points that failed the upper or lower 
bounds of acceptance.  
 
 
 
 
 
 
Figure 3.2: Example dose distributions for a single patient, showing 3D1cm (a), 3DTreat 
(b), RA64 (c) and RA70 (d). PTV1cm is shown in all plans. The dose colour wash runs 
from the 90% isodose line through to the respective dose maximum. 
 
  (a) 
  (d)   (c) 
  (b) 
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The investigated clinical problem is evident in the above results with seven 3D1cm 
plans failing at least one rectal dose constraint and only three passing all the imposed 
acceptance criteria, evidence to the point that 3DCRT is unable to treat an 
uncompromised treatment volume without failing dose constraints (table 3.2) and over 
dosing the rectum. This issue is resolved through the reduction of the posterior PTV 
border, as nine out of ten 3Dtreat plans meet both the rectal constraints, although the 
risk of geographical miss is significantly increased. Only six of these plans passed all 
the acceptance criteria, although nine did pass the rectal constraints, conformity and 
homogeneity acceptance. The compromise in PTV volume is completely avoided 
through the use of RA planning techniques, with all 10 RA64 plans meeting the 
imposed acceptance criteria. Nine of the RA70 plans met both of the rectal dose 
constraint whilst a single plan failed the verification acceptance criteria, resulting in a 
total of eight plans meeting all the imposed criteria. The mean value for the 
ArcCHECK absolute gamma was 94.1%. 
  
Number of plans meeting criteria 
 
Acceptance 
criteria 
RA70 RA64 3DTreat 3D1cm 
Rectum 
D40%<60Gy 9/10 10/10 10/10 4/10 
D60%<40Gy 10/10 10/10 9/10 4/10 
PTV 
D50%=P±0.5% 10/10 10/10 8/10 8/10 
D98%>0.95*P 10/10 10/10 9/10 9/10 
D3%<1.05*P 10/10 10/10 9/10 9/10 
CI95<1.5 - - 10/10 10/10 
CI95<1.2 10/10 10/10 - - 
HI>90% 10/10 10/10 10/10 10/10 
ArcCHECK γ3%,3mm>90% 9/10 - - - 
All criteria Pass all above 8/10 10/10 6/10 3/10 
 
Table 3.2: Plan acceptance criteria summary.  
                  P = prescribed dose 
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 RA70 RA64 3DTreat 3D1cm Significance 
Rectum 
R40% 47.6 43.2 51.8 58.6 α γ θ ι 
R60% 24.0 22.3 34.1 43.4 α γ ζ ι 
Rmean 38.2 34.9 41.2 45.7 α γ ζ ι 
Rmax 73.4 67.4 65.1 65.2 ε 
EUD 58.6 52.9 54.2 57.1 α γ η κ 
PTV 
D50% 70.0 64.0 63.8 64.2 - 
D98% 67.1 61.4 61.8 61.7 δ 
D2% 72.4 66.5 65.8 66.2 ∆ 
CI95 1.1 1.1 1.3 1.3 λ µ 
HI 93.8 93.3 94.3 94.2 β γ λ µ 
 MU 867.6 810.7 271.3 268.6 λ µ 
 
Table 3.3: Planning parameter comparison. Statistical comparisons are outlined in 
column 7. αRA70 < 3D1cm, βRA70 vs. 3D1cm NS, γRA64 < 3D1cm, δRA64 vs. 3D1cm NS,     
εRA64 > 3D1cm, ζRA70 < 3DTreat, ηRA70 > 3DTreat, θRA70 vs. 3DTreat NS, ιRA64 < 3DTreat,     
κRA64 vs. 3DTreat NS, λRA70 vs. RA64 NS, µ3DTreat vs. 3D1cm NS. 
 
Across the patient cohort, the rectal sparing parameters (R40%, R60%, Rmean and EUD) 
were significantly less for RA64 than both conformal techniques, although the 
maximal dose point (Rmax) was slightly higher. This significant improvement over 
conformal was mirrored for RA70, excluding the EUD. On average the RA70 EUD was 
1.5 and 4.5 Gy more than 3D1cm and 3Dtreat respectively, mainly due to the fact that 
volumes of the rectum received doses above 64 Gy (the prescribed dose of all the 
other plans). The conformity of the RA plans was better than that of the 3D 
techniques, but the reverse is true with respect to homogeneity. More MUs (table 3.3, 
row 12) were required for both RA plans over both 3D plans but no significant intra-
technique differences were observed. 
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Figure 3.3: Mean DVHs for the target (a) and rectal (b) volumes. 
 
 
 
(b) 
(a) 
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Figure 3.4: Example ArcCHECK gamma comparison for a single patient. Shown is 
the planned dose map with failed points superimposed. In this example the failed 
points represent 3.7% of all investigated points. 
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3.4 Discussion 
The major advantage of intensity modulated radiotherapy techniques is their ability to 
reduce the dose to critical normal tissues. In prostate bed radiotherapy the rectum is a 
major dose limiting structure and reducing the dose it receives may reduce toxicity. 
Safe dose escalation has been shown to be feasible using fixed gantry IMRT in this 
setting and low rates of toxicity are reported even with significant dose escalation 
[106, 112, 113]. However, the increased MU required for these techniques can 
prolong the time required for treatment and thus reduce efficiency. The average RA 
(RA64 and RA70) beam on time was 2.3 minutes and although no quantitative 
comparisons with 3D techniques are made, it is expected that RA plans would be 
treated in the same 10 minute time slot as conformal treatments and thus negating the 
historical disadvantage of intensity modulated deliveries.  
 
This planning study investigated prostate bed irradiation in 10 patients previously 
treated with conformal radiotherapy. Using conformal radiotherapy and a uniform 1 
cm CTV→ PTV expansion it was difficult to meet the pre-defined rectal dose 
constraints in most patient cases. Moreover, even with a reduction of the posterior 
PTV expansion to 0.5 cm it was still not possible to meet these constraints in many 
cases. Decreasing the PTV further has allowed the defined rectal dose constraints to 
be met but at an increased risk of geographical miss. Using surgical clips and on 
board imaging to study prostate bed motion, one study has suggested that movement 
of more than 5 mm may be seen in 27% of patients in this setting [106]. Similar 
findings have also been reported by Schiffner et. al. who used fiducial markers to 
describe movement in the prostate bed; their study suggests that using bone 
localisation more than 5 mm of movement may occur on nearly 40% of treatment 
days [114], suggesting that at a bare minimum of 5 mm expansion should be used, 
with 1 cm being preferable. Although not the concentration of the current work, the 
potential for reducing these margins may also be safely achieved through the 
implementation of daily image guidance (cone-beam CT and orthogonal 2D kV 
images) and soft tissue matching. Due to the conformal nature of RA techniques, 
imaging of this nature is also a pre-requisite for successful implementation, within the 
clinic.  
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This planning study has shown that RA techniques provide the ability to treat the 
prostate bed without comprising the target volume, whilst at the same time improving 
rectal sparing, compared to what has been previously treated locally. Moreover, it has 
been shown that escalating the prescribed dose to this volume by a further 6 Gy is 
feasible, in the majority of patients. As seen in figure 1, the average rectal dose for 
RA70 is less than both conformal techniques for 70% of the volume, although almost 
30% of the volume receives more than the conformal prescribed dose of 64Gy. As a 
result, the RA70 rectal EUD is larger than of the previously treated cohort. This 
increase seems justified due to current toxicity data and the results of previously 
published studies. Escalation of this nature still needs to be considered on a patient-
by-patient basis due to the fact that two of the ten RA70 plans failed one of the 
imposed acceptance criteria. One patient failed a rectal dose constraint and one the 
pass criteria of the ArcCHECK verification. These failures were rectified by reduction 
of the PTV posterior border to 8 mm and restricting the optimisation MUs to less than 
650, as to improve rectal sparing and reduce over modulation respectively. In both 
cases the integrity of the plans were maintained whilst in the former the R60% reduced 
below 40 Gy and the latter, the gamma improved to a point where agreement was 
above the 90% criteria. Conclusions based on ArcCHECK measurements are limited 
due the fact that the devise is novel and the associated measurement capabilities and 
limitations are still unknown (discussed further in 5.1). Further RA verification 
measurements using other devices are conducted as part of the subsequent chapter.   
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3.5 Concluding Remarks  
The planning strategy presented in chapter 2 has been modified to fit the needs of a 
related but independent patient group with the goal of maintaining target volume 
integrity and investigating the feasibility of safe dose escalation. The ability of RA 
optimisation to produce concave and sharp dose gradients has completely satisfied the 
former goal, with the full patient cohort meeting OAR dose and plan constraints, even 
when a 1 cm CTV→PTV expansion was implemented, and hence the risk for 
geographical miss is reduced without increasing the expected toxicity. 
Implementation of RA optimisation has also shown that dose escalation up to 70 Gy is 
feasible on a patient-by-patient basis. Care needs to be taken not to over-modulate 
plans or produce patient geometries where large volumes of rectum overlap with the 
PTV. If these issues do arise the potential to restrict the plan MUs and reduce the 
PTV’s posterior border exists, although further work on the former is still required. 
The increased rectal EUD in this dose escalated patient group may result in an 
increased level of toxicity, although previously published data suggests that this may 
be justified. It is suggested that escalation of this type be accompanied by daily soft 
tissue registration image guidance and extensive early and late patient follow up.    
 
Plan verification is essential for complex delivery techniques such as RA whereby 
discrepancies between the planned and measured dose may be a culmination of many 
parameters including: the ability for the TPS to model the dose from complex and 
often small MLC apertures (Figure 2.7), accuracy of the measurement (ArcCHECK) 
hardware, linac variations and experimental uncertainty. If we are to reduce many of 
these discrepancies involved with this still novel and complex delivery techniques 
then the origin of these must be further investigated. To address only one of these 
issues, the ability and accuracy of the Eclipse TPS to model complex dose 
distributions and delivery techniques, is the concentration of the subsequent chapter. 
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Chapter 4 – Configuration of the Anisotropic 
Analytic Algorithm  
 
4.1 Introduction 
The anisotropic analytic algorithm (AAA) is Varian Medical System’s 
implementation of the superposition/convolution type algorithm, originally developed 
by Ulmer et. al. [115, 116]. This type of algorithm currently dominates commercial 
TPSs due to its improved calculation of lateral electron transport when compared with 
other dose calculations algorithms; such as the pencil beam convolution (PBC) 
algorithm [117, 118]. This improvement in lateral electron transport is especially 
important when dealing with heterogeneous media [118], such as lung and bone. In 
saying this, the gold standard of dose calculation is still regarded as Monte Carlo 
(MC) models [119, 120]. The main reason full MC calculation models are not 
implemented in commercial TPSs is due to the fact that they are computationally 
heavy, resulting in increased calculation times when compared with AAA. 
 
Configuration of the AAA in the Eclipse TPS requires a variety of linac beam 
parameters as input data [67]. As a minimum this includes: beam profiles at a range of 
depths (Dmax, 50, 100, 200, and 300 mm) for field sizes ranging from 3x3 to 40x40 
cm, diagonal 40x40 cm profiles,  percentage depth doses (PDDs) and output factors 
(OF) for the full range of field sizes. Generally, this beam data is manually measured 
and is therefore linac - or at least institution – dependent, and as a result, separately 
configured algorithms are unique in nature. As per Varian’s recommendation, beam 
data is conventionally collected with the linac jaws (secondary collimator) defining 
the field edge [66, 67]. The physical penumbra of fields defined by either the jaw or 
MLC vary from one another due to multiple factors, including inter-leaf leakage and 
the transmission and scatter off the rounded leaf tips (see figure 1.4). Conventionally, 
these variations are accounted for within the Eclipse TPS, by leaf transmission and 
dosimetric leaf gap (DLG) factors. The MLC transmission factor accounts for 
transmission through the leaves and mainly affects the umbra region (defined as the 
region outside the lower penumbral point, 20%). The DLG accounts for the increased 
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transmission through the rounded leaf tips, whereby fields defined by the MLC are 
effectively made wider by the magnitude of the DLG [121, 122]. Neither of these 
factors account for differences in penumbral shape of the jaws and MLCs. 
     
Although good agreement between the AAA and novel verifications measurements 
(ArcCHECK) has been observed over the whole arc (chapter 3), observations by other 
authors (Gange et. al. [123]) have indicated large errors for single RA control points, 
despite the fact that MLC transmission is modeled by transmission factors. Part of the 
study by Gange et. al. benchmarked a single irregular MLC control point against MC 
calculations. Consistent discrepancies on the order of 5% were observed across a 
single leaf end penumbra, and 12% across an isolated leaf edge. The authors postulate 
that the errors in MLC modeling may results in errors on the order of 1.5% over the 
full arc [123]. 
 
 The AAA has been previously verified for fields defined by static MLCs [124] but 
the question still remains if the AAA more accurately models MLC defined fields if 
the configuration beam data is collected with the MLC rather than the jaws defining 
the field. This question is especially pertinent when considering highly modulated 
fields where the MLC constantly defines the field edge, as is the case with both static 
and rotational IMRT (figure 2.7). In the present study, two separate AAAs are 
configured using beam data collected with either the jaw or the MLC defining the 
field edge with the hypothesis that this may improve the modeling of MLCs and 
reduce potential calculation errors that are involved with highly modulated plans. An 
extensive comparison between the two algorithms follows, including comparisons 
with static and dynamic fields in solid water, anthropomorphic phantoms and patient 
anatomies. Comparisons with physical verification methods are also performed. 
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4.2 Materials and Methods 
4.2.1 The AAA 
When calculating the dose from a single field (or control point) the AAA splits the 
field into multiple smaller sub-fields, or beamlets (β) [67]. The dose contribution from 
each beamlet is then calculated using convolution methods. Throughout this process, 
the energy fluence from each beamlet is split into three separate dose contributing 
components; primary photons, extra-focal photons and contamination electrons 
(originating in the flattening filter, ion chamber, collimator and air) [125]. The 
relevant convolution equation is as follows: 
∫∫ −−××Φ=
β
ββββ ρρ
'''' ),,,(),(),,( dydxzyyxxKzIzyxD , (9) 
where the dose contribution from each beamlet is Dβ(x,y,z), Φβ is the beamlet fluence, 
Iβ(z,ρ) is the energy deposition density function, and K(x,y,z,ρ) is the MC derived 
scatter kernel [66, 67, 115]. Each of these functions are defined separately for the 
three dose components and therefore calculated independently from one another. Not 
only are the energy fluence and the scatter kernel analytic functions, the convolution 
integral has been solved analytically, hence the leading A in the algorithms name. The 
second A comes from the fact that each scatter kernel is evaluated in multiple 
anisotropic directions from the beamlet. Following each individual convolution, the 
dose at a point, D(x,y,z), is calculated as the superposition of all three dose 
components over all beamlets [66].     
 
4.2.2 Beam Configuration 
All beam cross-plane profiles and PDDs (unless otherwise stated all presented PDDs 
are normalised to 5cm) were measured at 100 cm source-to-skin distance (SSD) in a 
PTW (Freiburg, Germany) MP3 water tank using a 0.125 cm3 PTW semiflex chamber 
and the software analysis and conversion done using the matched PTW Mephysto 
Mc2 program. OFs were measured in either the Med-tec (TruMed Healthcare, Orange 
city, Iowa, USA) or PTW MP3 water tanks (dependent on field size) using the same 
semiflex chamber, at 100 cm source-to-axis distance (SAD) with a reference depth of 
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5 cm in a 10x10 cm field. The chamber was offset to the effective point of 
measurement in the depth axis.  
 
Two independent sets of beam data were collected on separate occasions, one with the 
jaws defining the field and one with the MLC. In the case where the MLC was 
defining the field, the jaws were placed at least 4 cm outside the MLC field edge. The 
largest field size being the only exception to this rule, whereby the jaw and MLC 
overlap due to the construction of the linac head. Positioning the jaws in this fashion 
meant that the jaws were a large enough distance away from the field edge as not to 
affect the measurement whilst not exposing the end of the leaf bank to radiation.   
Profile measurements ran perpendicular to the MLC, with the converging point of the 
MLC, off-set from the axis of chamber motion. Both of these data sets were restricted 
to 6 MV only. Beam profiles were measured at depths of Dmax, 5, 10, 20 and 30 cm 
for field sixes 3x3, 4x4, 6x6, 8x8, 10x10, 20x20, 30x30, and 40x40 cm and diagonal 
scans for the largest field. All profiles were measured at least 3.5 cm past the field 
edge (defined at 50% of full width at half maximum (FWHM)). In the case where 
measurements were limited by the tank geometry (40x40 cm), half profiles were 
measured and then symmetrised. Central axis PDDs were also measured for each of 
the above stated field sizes. All of this data were then symmetrised and smoothed in 
the Myphesto Mc2 software. As a representative example of these data sets, the full 
MLC defined half-beam profile and PDD set can be found in figure 4.1 (a) and (b) 
respectively. OFs for a sample of the above field sizes were measured and then the 
remainder of the data set interpolated in Microsoft Excel. Both of these data sets were 
then converted to Ascii format in preparation for importation into the Eclipse TPS for 
beam configuration. 
 
The first algorithm was configured using the jaw defined data set, henceforth referred 
to as AAAJaw. This algorithm was subjected to an extensive commissioning program 
including inter-comparisons with the then clinical PBC, in homogeneous and 
inhomogeneous media (bone and lung) using point dose chamber measurements as a 
benchmark. The results of this study were inline with previously published data [118, 
119, 124, 126]. The majority of AAAJaw calculated point doses were within 3% of the 
measured data, and in general improved over the PBC. This algorithm was 
subsequently released for clinical use for 3DCRT calculations. The second algorithm, 
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AAAMLC, was later configured using the MLC collected data set and identical OFs. 
All other user defined parameters such and the MLC leaf transmission and DLG were 
set as to align with locally measured values (1.4% and 2.1 mm respectively) and were 
consistent across both algorithms. To reiterate from 2.1.2.3, the dose grid size used in 
all AAA calculations was 2.5 mm.       
 
 
Figure 4.1: Half-beam profiles (a) and central axis PDDs (b) (normalised to dmax) for 
the full AAAMLC data set. 
  
(a) 
(b) 
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4.2.3 Algorithm Comparison 
4.2.3.1 Measured Data 
The first step in establishing differences between the two AAAs was to compare the 
measured data that went into configuring them. The field sizes and physical 
penumbras (defined as the distance between the 80 and 20% points) was tabulated for 
all input data. The measured PDDs were compared at three depths, Dmax, D80 and D50, 
where D is the depth denoted by the subscript, as a percentage of dose. Following 
configuration, the Eclipse TPS calculates average gamma errors between the input 
and output data for points including: within the field, in the penumbra region and 
outside the field. A comparison of these errors is also presented.  
 
Statistical analysis done throughout used a one sided, two paired sample T test and 
differences were deemed statistically significant if p ≤ 0.05. 
 
4.2.3.2 Phantom Comparisons 
Various inter-comparisons were made between the two AAA algorithms in virtual and 
physical CT scanned phantoms. This process started with simple comparisons 
between open fields simulating the geometry under which the original data was 
acquired (jaw and MLC defined fields). A virtual water phantom (cube) of dimensions 
50 cm3 and uniform density (HU=0) was created in the Eclipse TPS and ant-post 
fields of sizes 3x3 and 10x10 cm added. Two separate plans were inserted for each 
size, one with the jaws defining the field and one with the MLC, and calculated with 
both algorithms, resulting in a total of eight individual plans. Beam profiles at depths 
of 1.5, 5 and 30 cm were then extracted through the central axis and PDDs at the 
centre of the field. Comparisons of the beam penumbra, field size and dose 
subtractions were made between the two algorithms and the corresponding measured 
data.  
4.2.3.3 Patient Treatment Plans 
All AAA calculations presented in the preceding chapters were done using the 
AAAJaw algorithm. To assess the differences in the two algorithms when calculating 
more complex RA plans, the 10 prostate patients from chapter 2 were recalculated 
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with AAAMLC and differences assessed through the global and PTV maximum point 
dose differences, volumetric dose subtraction (AAAJaw -AAAMLC), dose difference 
profiles and the mean PTV3 dose. The clinical significance of any observed difference 
in the PTV dose was assessed through calculation of EUD based TCPs using methods 
published by Gay and Niemierko [127]. This method requires PTV DVH data and 
several radiobiological parameters such as the alpha beta ratio (α/β), the dose-
response curve parameter (γ50), the mean dose to control 50% of tumors (TCD50) and 
the previously described tumor specific parameter, a. Prostate specific values for these 
parameters were taken from the literature: α/β = 3.1 [128], γ50 = 2.9 [129], TCD50 = 
70.5Gy [129] and a = -10 [130]. A sub set of these comparisons were completed for 
more complex treatment plans including double arc treatments of the thyroid bed and 
brain.  
4.2.3.4 Verification Measurements 
Ion chamber point dose measurements were completed to assess the accuracy of the 
two algorithms. Verification plans for a random selection of five prostate RA plans 
(from chapter 2) were created in the Eclipse TPS. These verification plans used a CT 
scan of the Computerized Imaging Reference Systems Inc. (CIRS) pelvis phantom 
(Fig 4.2) and the RA plan calculated using both algorithms. Farmer (0.6 cm3) (points 
1, 2 and 4) and semiflex (0.125 cm3) (point 3) chamber volumes were contoured at 
four locations corresponding to the bladder - PTV interface, PTV, rectum - PTV 
interface and femoral head. The mean dose of each chamber volume was extracted. 
Each plan was then delivered a total of 12 (four points by three repeat measurements) 
times on a Varian iX linac and the measured chamber values compared with those 
calculated by the two algorithms. To stress the algorithms further, the above 
verification process was repeated for a simulated lung treatment in a thorax CIRS 
phantom at three points (Figure 4.3) again using both the farmer (point 5) and 
semiflex (point 6 and 7) chambers, and again compared with both AAA calculated 
mean dose values. All percentage differences are calculated using AAPM Task Group 
119 formalism (100*[(measured dose)-(planned dose)]/prescribed dose) [131].  
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Figure 4.2: AAA verification using the CIRS pelvis phantom and chamber point 
measurements 
 
 
 
Figure 4.3: AAA verification using the CIRS thorax phantom and chamber point 
measurements.  
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4.3 Results 
4.3.1 Algorithm Comparison 
4.3.1.1 Measured Data 
Example comparisons of the measured beam profiles can be found in Figure 4.4 
(3x3cm) and Fig 4.5 (10x10 cm) and a full summary of the field size and penumbral 
values in table 4.1. There is no overall trend between the measured jaw and MLC 
defined field sizes. Some jaw defined fields are larger, other MLC defined fields are 
larger and some show non-significant differences. However, consistent with MLC and 
jaw radiation transmission, this is not the case when it comes to the measured 
penumbras. A strong trend is observed, indicating that the MLC defined fields have a 
lager penumbra over the range of field sizes (except the largest 40x40 cm due to the 
fact that the geometry is identical for both (jaw and MLC overlap)). Although not 
quantitatively addressed, it can be seen from figures 4.4 and 4.5 that the MLC defined 
fields not only have larger penumbras but higher doses in the umbra region. 
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Figure 4.4: Comparison of measured jaw and MLC defined 3x3cm profiles at 5cm 
depth. 
 
 
Figure 4.5: Comparison of jaw and MLC defined measured 10x10cm profiles at 5cm 
depth. 
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Field 
size 
(cm) 
Depth 
(mm) 
Field size (cm) 
Significance 
Penumbra 
Significance 
Jaw MLC Jaw MLC 
3x3 
15 3.05 3.01 
Jaw>MLC 
4.71 5.80 
Jaw<MLC 
50 3.16 3.13 5.02 6.18 
100 3.31 3.28 5.21 6.35 
200 3.62 3.60 5.64 6.92 
300 3.93 3.90 5.87 7.13 
4x4 
15 4.06 4.02 
Jaw>MLC 
 
 
4.38 6.35 
Jaw<MLC 
 
 
50 4.20 4.17 5.16 6.99 
100 4.42 4.39 5.44 7.35 
200 4.83 4.81 5.95 8.16 
300 5.24 5.21 6.38 8.70 
6x6 
15 6.10 6.05 
Jaw>MLC 
 
 
4.94 6.57 
Jaw<MLC 
 
 
50 6.31 6.26 5.38 7.31 
100 6.62 6.57 5.86 7.96 
200 7.24 7.20 6.65 9.17 
300 7.85 7.81 7.38 9.97 
8x8 
15 8.12 8.31 
Jaw<MLC 
 
 
5.07 6.49 
Jaw<MLC 
 
 
50 8.41 8.61 5.57 7.20 
100 8.82 9.03 6.22 8.15 
200 9.64 9.89 7.45 10.00 
300 10.45 10.74 8.64 11.89 
10x10 
15 10.15 10.36 
Jaw<MLC 
 
 
5.08 6.51 
Jaw<MLC 
 
 
50 10.50 10.72 5.67 7.28 
100 11.01 11.25 6.49 8.46 
200 12.03 12.30 8.15 10.88 
300 13.05 13.35 10.16 13.77 
20x20 
15 20.37 21.52 NS 
 
 
5.24 6.73 Jaw<MLC 
 
 
50 21.07 21.23 6.13 7.86 
100 22.07 22.24 7.65 9.98 
200 24.08 24.28 12.69 16.22 
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300 26.08 26.31 20.55 24.46 
30x30 
15 30.57 30.38 
NS 
 
 
5.28 6.81 
Jaw<MLC 
 
 
50 31.62 31.74 6.38 8.32 
100 33.11 33.24 8.65 11.50 
200 36.08 36.24 17.74 21.10 
300 39.05 39.23 32.92 35.05 
40x40 
15 40.83 40.62 
Jaw>MLC 
 
 
5.25 6.13 
NS 
 
 
50 42.23 42.01 6.63 7.15 
100 44.19 43.99 9.83 10.15 
200 48.24 47.93 21.48 21.50 
300 52.25 52.00 45.76 43.83 
 
Table 4.1: Measured profile comparison for jaw and MLC defined fields. Fields sizes 
and penumbral vales are presented for the full range of field sizes and depths in the 
data set along with statistical comparisons.   
 
Comparisons of the measured PDDs can be found in Figure 4.6 (a) (3x3 cm) and 
Figure 4.7 (10x10 cm) and a summary of the percentage depth values in table 4.2. An 
example PDD subtraction (measured jaw PDD - MLC PDD) is also presented in 
Figure 4.6 (b). No statistical differences are seen in the build up region however 
variations are seen at depth. Both the D50 and D80 are larger for the jaw defined field, 
across the range of field sizes. As these differences are small, the trend can be more 
easily visualised in figure 4.6 (b), with the jaw defined field PDD consistently larger 
than that of the MLC for depths larger than 50 mm. The maximum percentage 
differences for D50 and D80 are 1.0 and 1.5% for respectively. The potential orientation 
of these small yet significant variations will be discussed in further detail below. 
Average gamma errors between each algorithm and the measured data can be found in 
table 4.3. As observed, the largest errors occur in the penumbra and outside the field, 
with larger differences between the measured MLC data and the configured AAAMLC. 
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Figure 4.6: Measured 3x3 cm jaw (largely obscured) and MLC PDDs for a 3x3 field 
(a). PDD subtraction (jaw-MLC) showing small yet consistent differences at depths 
larger than 50 mm (b).  
 
 
Figure 4.7: Measured jaw (largely obscured) and MLC PDDs for a 10x10 cm field.  
 
(b) 
(a) 
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Filed size 
(cm) 
Dmax (mm) D80 (mm) D50 (mm) 
Jaw MLC Jaw MLC Jaw MLC 
3x3 13.5 14.0 54.8 54.1 129.7 128.4 
4x4 14.5 13.0 56.9 56.4 133.6 132.3 
6x6 13.5 14.0 59.7 59.6 140.0 139.5 
8x8 13.1 13.0 61.9 61.7 146.2 145.0 
10x10 14.0 13.0 64.1 63.1 151.0 149.7 
20x20 11.1 12.0 68.5 67.5 166.2 164.7 
30x30 12.0 11.0 70.7 70.3 174.1 173.2 
40x40 11.0 11.0 72.6 72.4 180.2 179.4 
Significance NS Jaw>MLC Jaw>MLC 
 
Table 4.2: Comparison of measured PDDs.  
 
 AAAJaw AAAMLC ∆ (AAAJaw-AAAMLC) 
Within field 0.15 0.12 0.03 
Penumbra 0.21 0.36 -0.15 
Outside field 0.34 0.87 -0.53 
 
Table 4.3: Average gamma errors between measured and configured data for the 
respective algorithms, within the field, penumbra and outside the field.  
 
4.3.1.2 Phantom Comparisons 
Figures 4.8 is presented as a comparison between a 3x3 cm MLC defined field 
calculated with the two AAA algorithms, although as can be observed any differences 
are indistinguishable. Figures 4.9 (a)-(b) are in analogy with figures 4.6 (a)-(b) but are 
presented as a comparison between the PDD of the two algorithms. The observed 
inter-algorithm values are small and insignificant. Figures 4.10-4.13 give comparisons 
between measured and calculated (AAAJaw) profiles for 3x3 and 10x10 cm jaw and 
MLC defined fields. Relatively good agreement is observed for the MLC and jaw 
defined 10x10 cm fields and the jaw defined 3x3 cm field (differences mainly a result 
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of the fact that the calculation grid size is large relative to the field size), although 
larger differences are observed for the 3x3 cm MLC defined field. A quantitative 
analysis of measured and configured field size and penumbra can also be found in 
tables 4.4 and 4.5 respectively. The agreement between measured and configured field 
size is generally good although large discrepancies are seen for small (3x3 cm) MLC 
defined fields, with the configured size consistently larger than the measured data. 
Larger errors between the measured and configured penumbra are observed across all 
investigated fields and depths. The overall trend in this data is that the configured 
penumbras are smaller than that of the measured, a result consistent with the 
observations of other authors [123].    
 
   
Figure 4.8: Profile comparison for a MLC defined field calculated with both AAAJaw 
(largely obscured) and AAAMLC. The profile presented is a 3x3 cm field and 5 cm 
depth. 
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Figure 4.9: AAAJaw (largely obscured) and AAAMLC PDDs for a 3x3 cm jaw defined 
field (a). Corresponding PDD subtraction (AAAJaw-AAAMLC) (b). 
 
 
 
 
(b) 
(a) 
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Figure 4.10: Comparison of AAAJaw calculated and measured 3x3 cm profiles with 
the jaw defining the field. Depth of measurement = 5cm. 
 
Figure 4.11: Comparison of AAAJaw calculated and measured 3x3 cm profiles with 
the MLC defining the field. Depth of measurement = 5cm. 
 
                                                                    80 
 
Figure 4.12: Comparison of AAAJaw calculated and measured 10x10 cm profiles with 
the jaw defining the field. Depth of measurement = 5cm. 
 
Figure 4.13: Comparison of AAAJaw calculated and measured 10x10 cm profiles with 
the MLC defining the field. Depth of measurement = 5cm. 
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4.3.1.3 Patient Treatment Plans 
A summary of data collected for the 10 prostate patient data set can be found in table 
4.6. This data reveals that the AAAJaw algorithm produces a significantly larger mean 
PTV3 dose. The mean global maximal point difference between the two plans - over 
the full 74 Gy treatment - is 0.90 Gy or 1.22%. The difference in maximum PTV dose 
is 0.52 Gy or 0.71%. As an assessment of the clinical significance of these differences 
the TCPs can be found in table 4.6. Plan and profile subtractions for prostate, thyroid 
bed and brain can be found in figures 4.14-16.  
 
 
Patient 
Mean PTV3 dose 
(Gy) 
TCP (%) Plan subtraction 
AAAJaw AAAMLC AAAJaw AAAMLC 
Abs 
max 
∆ 
(Gy) 
Abs 
max 
∆ 
(%) 
PTV 
max 
dose 
∆ 
(Gy) 
PTV 
max 
dose 
∆ 
(%) 
1 75.90 75.46 72.1 70.2 0.80 1.08 0.52 0.70 
2 74.59 74.14 66.0 63.8 0.60 0.81 0.53 0.71 
3 73.70 73.33 61.6 59.7 0.95 1.28 0.49 0.66 
4 73.32 72.25 59.7 57.1 0.86 1.16 0.54 0.73 
5 73.88 73.47 62.6 60.5 0.95 1.28 0.50 0.68 
6 73.72 73.24 61.6 59.1 0.85 1.15 0.55 0.74 
7 75.19 74.71 69.0 66.7 0.88 1.19 0.53 0.72 
8 75.21 74.77 68.9 66.8 1.11 1.50 0.52 0.70 
9 73.88 73.43 62.5 60.2 1.07 1.45 0.52 0.71 
10 73.77 73.37 59.5 58.3 0.97 1.31 0.55 0.74 
Average 74.31 73.82 64.3 62.2 0.90 1.22 0.52 0.71 
Significance AAAJaw>AAAMLC AAAJaw>AAAMLC - - - - 
 
Table 4.6: PTV3 and plan subtraction data for differences in dose calculated with 
AAAJaw and AAAMLC for 10 prostate RA plans. Dose differences are presented as 
absolute values.  
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Figure 4.14: RA prostate doe subtraction (AAAJaw - AAAMLC) (a). The red line 
represents the plane and direction in which a dose subtraction profile was taken, as 
presented in (b). 
 
 
(b) 
(a) 
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Figure 4.15: RA thyroid bed doe subtraction (AAAJaw - AAAMLC) (a). The red line 
represents the plane and direction in which a dose subtraction profile was taken, as 
presented in (b). 
 
 
 
(b) 
(a) 
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Figure 4.16: RA brain doe subtraction (AAAJaw - AAAMLC) (a). The red line 
represents the plane and direction in which a dose subtraction profile was taken, as 
presented in (b).  
 
 
 
 
 
 
(b) 
(a) 
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4.3.1.4 Verification Measurements 
A summary of point dose verification measurements can be found in table 4.7. Across 
both the prostate verification and lung simulation measurements 23 points were 
investigated. AAAJaw more accurately predicted the measured dose on 10 occasions 
and AAAMLC on 13. The mean absolute difference between the presented values was 
0.34%, within the experimental uncertainty of the measurement process. In general 
measurements for both algorithms were in good agreement with the exception of point 
3 (rectum - PTV interface), largely due to the fact that the chamber often fell in a 
steep dose gradient. No other intra-patient or single point trends were observed.  
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Patient Chamber point ∆ AAAJaw (%) ∆ AAAMLC (%) 
1 
1 -0.20 0.20 
2 0.06 0.61 
3 -4.05 -3.65 
4 0.01 0.21 
2 
1 -0.97 -0.17 
2 -1.04 -0.44 
3 -10.35 -10.10 
4 -0.55 -0.35 
3 
1 2.81 3.26 
2 1.68 2.13 
3 -6.99 -6.79 
4 -0.10 0.05 
4 
1 1.14 1.64 
2 -0.01 0.59 
3 -10.23 -9.98 
4 1.51 1.66 
5 
1 1.20 1.60 
2 -0.78 -0.23 
3 -2.91 -2.41 
4 -1.36 -1.16 
- 
5 0.63 0.80 
6 -0.29 -0.01 
7 2.10 2.20 
 
Table 4.7: Summary of point dose verification measurements. Prostate verification 
measurements (points 1-4) are presented as patients 1-5 whereas the simulated lung 
treatment (points 5-7) does not have an assigned patient number. 
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4.4 Discussion 
The observed differences in the measured beam profiles is consistent with the known 
difference in transmission of the jaw and MLC field defining ends [132], whereby the 
penumbra of the MLC defined field being larger than that of the jaw, for all field sizes 
smaller than 40x40 cm. The difference between the mean penumbral values of the 
measured jaw and MLC fields was 2.1mm. Although this value is small, it may be 
significant when field sizes are small, as is the case with highly modulated static and 
dynamic IMRT plans. The small yet significant difference between the measured 
PDDs was unexpected, as central axis radiation transport is often at a distance large 
enough not to be effected by the field edge. Further investigations has revealed no 
consistent variation in energy (and therefore depth dose) when either the jaws or 
MLCs are defining the field. Thus, it is concluded that the observed differences are a 
result of discrete measurement set-up and not the linac head geometry itself.   
 
Various conclusions can be drawn from analysis of the two algorithms, given the 
observed differences in the profile and PDD input data. This configuration process 
seems to be very sensitive to the PDD input data but not that of the beam profiles. The 
differences in measured dose at depth have carried through the configuration process, 
but the observed penumbras for both jaw and MLC defined fields are almost identical 
for both algorithms, even though the input data was distinctly different. This is an 
important result, as any further differences between the algorithms can no longer be 
fully associated with the differences in measured beam profiles (and therefore the jaw 
or MLC defining the field), but must be largely due to the observed differences in the 
PDDs at depth. Both of the algorithms model the field edge and penumbra of jaw 
defined fields well across all the investigated field sizes, but this is not the case for 
MLC defined fields. Larger field sizes are modeled well but more significant 
discrepancies are observed for smaller field sizes. This fact again reinforcing the 
notion that highly modulated IMRT plans - or single control points - may not be 
modeled well by either AAA. 
 
The largest differences between the calculated RA plans were observed on the patient 
surface and at depth. The differences at the surface often fluctuated between either 
algorithm calculating more or less dose. However, AAAJaw consistently calculated 
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more dose than AAAMLC, at depth. These observations were consistent for all the 
investigated plans: including all 10 prostate plans, the thyroid bed and brain case. 
Measurement and modeling of the build-up region is challenging and inaccurate, and 
with the low doses involved, is likely to be clinically insignificant. The observed 
differences at depth are consistent with the differences in measured and AAA 
calculated PDDs for static fields. The mean PTV dose and TCP is significantly larger 
for AAAJaw than for AAAMLC, although the chamber point dose investigations reveal 
that neither algorithm systematically predicts the dose more accurately than the other. 
Without a measurement device accurate enough to discriminate the accuracy of these 
small differences, no conclusions can be drawn as to weather one algorithm is 
preferred over the other.      
 
Although no major differences have been observed between the two algorithms, 
further investigation have been performed as to improve the understanding of how the 
AAA is configured and how dose is calculated. As a measure of the sensitivity of 
individual configurations a third algorithm was configured using the exact same beam 
data that went into the original algorithm (AAAJaw). Subsequently, this AAA was 
used to retrospectively re-calculate already existing RA plans - such as those 
presented throughout the manuscript - and plan subtractions acquired. An individual 
RA plan was also repetitively calculated 10 times with a single algorithm and 
different permutations of plan subtractions acquired. In both of the above 
investigations negligible differences in calculated dose were observed and therefore it 
is concluded that both the configuration of and individual AAA calculations are a 
stable processes, and as a corollary, the observed minor differences in AAAJaw and 
AAAMLC are not a result of variations in either of these processes.  
 
Although conclusions can be drawn from the present study, there are major limitations 
and outstanding work that remains. Firstly, the configuration process is obviously a 
complex process and conclusions regarding the input data are convoluted with other 
related parameters such as the jaw and MLC transmission factors and the DLG. 
Secondly, the verification measurements are of a very discrete nature and the detector 
is of a one-dimensional (1D) nature. A more comprehensive verification comparison 
would set a more robust benchmark for the two algorithms to be compared against. 
This should include comparisons with 2D (film) or 3D (polymer gels) dosimeters and 
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independent MC calculations. It would be expected that with these verification 
techniques a robust and collective benchmark for both algorithms would be formed 
although these measures may still not be sensitive enough to inter-compare the two 
algorithms. A semiflex ion chamber has been employed to measure the majority of 
beam data utilised in this study and although this detector is small relative to a Farmer 
chamber, the accuracy of measurements of small field sizes (≤3x3 cm) is reduced 
[133]. Further work includes expanding the data set into smaller field sizes, through 
the use of a photon diode, diamond detector, liquid ion chamber or similar detector 
appropriate for measuring small field sizes. Further investigations to analyze the 
effect this extra input data has on the configuration of the AAA, would follow. A 
quantitative study comparing the accuracy of AAA dose calculation and verification 
measurements (ArcCHECK and other) dependent on the number of MUs and level of 
plan modulation is also of high importance. Comparisons with non 
superposition/convolution algorithms – such as Acuros [134] – is also of interest.       
 
The major limiting factor in the above study is that the two data sets were collected 
during different measurement sessions, possibly resulting in variations that convolute 
the property that was being investigated, namely the variation in the penumbra for jaw 
and MLC defined fields. This complicating factor could be removed – and more 
robust conclusions drawn – by measurement of the two data sets during the same 
measurement session, or configuration of two algorithms using two identical sets of 
PDDs. Varian provides so called ‘golden beam data’ that is representative of a linac 
type but not an individual machine (or set of beam matched machines). The observed 
configuration insensitivity to input beam profiles begs the question; are user measured 
profiles required at all, or should golden beam data be used as a surrogate? 
Configuration and analysis of a golden AAA is also in the realms of interesting future 
work. 
 
 
  
                                                                    90 
4.5 Concluding Remarks 
Configuration of the AAA in the Eclipse TPS has been shown to be sensitive to PDD 
input and insensitive to profile input. This extreme sensitivity to PDD input has 
important consequences for institutions with multiple linacs. Unless the energy 
matching of these machines is very close it is recommended that multiple machine 
dependent algorithms be configured, as to reduce potential differences in dose at 
depth. As a result of the insensitivity to beam profile input, beam data can be collected 
with either the jaws or MLCs defining the field edge, although the former is 
recommended. Measurement in this manner is more robust, as measurements are 
insensitive to MLC positional errors and are less complex. The need for multiple 
algorithms (one for intensity modulated and conformal calculations) is also removed. 
Although the investigations in this chapter have produced a null result, the 
significance of this result is important with several recommendations coming as a 
consequence. The medical physics community must be vigilant when it comes to 
understanding the accuracy and limitations of the algorithms used to calculate dose, 
especially when complex and novel techniques such as RA are being utilised. The 
work presented in this chapter is just one of many steps that must be taken to improve 
this understanding. 
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Chapter 5 – Concluding Remarks 
 
The work presented herein has improved the overall knowledge of RA optimisation 
and dose calculation whilst exploring new clinical applications. Several previously 
unanswered questions (1.4) relating to these topics have also been addressed. 
However, this was not achieved without limitation. The goal of the subsequent 
sections is to outline these limitations, expand on future work and conclude the 
overall findings. 
 
5.1 Critical Analysis  
As outlined in chapter 2, there are many user defined parameters that affect the quality 
of the resulting optimisation. A specific combination of these parameters is outlined in 
the planning strategy, the results of which are inline with previously published data, at 
least for the treatment of prostate. It is difficult to isolate each of these parameters and 
therefore independently quantify the effect of variations in them. Formal planning 
studies would at least go some way to improving the understanding of what values 
should be selected, and potentially improve the possibility for the most optimum plan 
resulting. First and foremost, the effect of collimator angle requires more attention, 
with plans ranging from 5° through to 45° being produces for a range of patient 
anatomies, with plan quality assessment using methods used throughout preceding 
chapters. The affect of beam energy (10 or even 18MV) is also of interest, along with 
flattening filter free treatments. Investigation on how the number of MUs affects plan 
quality, overall modulation and agreement with verification measurements is the topic 
of other outstanding work. Investigating these effects could be achieved through 
manually restriction the MU value during repeated optimisations. The final planning 
limitation is related to the fact that only prostate and prostate bed treatments have 
been formally investigated. Further work is required to extend the presented data to 
other and often more complicated treatment sites such as head & neck. 
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The verification measurements presented in chapters 2 and 3 were limited to ion 
chamber and novel diode based measurements. Further verification measurements 
using a larger variety of detectors such as radiochromic film (currently unavailable in 
the WBCC) for both the investigated treatment sites is required. This would provide 
more confidence in the optimisation, modeling and delivery chain, and give more 
weight to the feasibility of delivery. With the highly modulated and irregular fields 
involved improvement in small field dosimetry is also of high importance, as outlined 
in 4.5. The fact that the ArcCHECK device is novel in nature also limits its use and 
the conclusions that can be drawn from it. This currently included the devises ability 
to accurately measure exit dose and the issue of the diode spatial resolution (1 cm) – 
in a single plane – being able to sufficiently resolve many of the small fields involved 
with delivery (figure 2.7). Further work is also required on the analysis of ArcCHECK 
results and what action levels should be set. Discrepancies between the planned and 
ArcCHECK measured dose is a convolution of many factors including; errors in CT 
acquisition, AAA dose calculation, set-up errors, diode response and spatial 
resolution. Deconvolving some of these factors may prove difficult, but still requires 
attention. As previously mentioned, the effect MU and overall modulation has on 
ArcCHECK results are also of interest. 
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5.2 Conclusions 
 
The planning and delivery of rotational IMRT techniques is on the cusp of both time 
and complexity. A search for the word ‘RapidArc’ on PubMed at the commencement 
of this work produced 10 results, whilst the same search produced 81 results at the 
time of submission. In this time period the technique has matured to a level where 
single institution annual data is now published, along with a plethora of planning 
studies for a wide variety of clinical sites. In a field that is so highly dependent on 
technology, planning studies of this nature must suffice as a method for comparison, 
but the scrutiny of phase III clinical trials beckons for not only rotational but static 
gantry intensity modulated techniques. When compared with traditional intensity 
modulated techniques, RA has been shown to be dosimetrically comparable, whilst 
allowing for reductions in both treatment time and MUs . This advantage comes at the 
cost of an even more complex and novel treatment, extending to the inverse planning 
process, dose calculation and the delivery and verification of treatment.  
 
To compliment the expanding data set of comparative planning studies a streamlined 
RA planning strategy - or class solution - has been formulated. This strategy gives 
detail regarding the initial field set-up, contouring, starting objectives, recommended 
optimisation user interactions and post-optimisation adjustments. The strategy was 
then applied to a cohort of 10 previously treated high and intermediate risk prostate 
patients. The resulting plans were then subject to an inter-comparative planning study 
with static gantry IMRT, as a justification for the planning strategy itself and not RA 
techniques in general, as has been previously published. The results of this study were 
shown to be generally comparable to previously published planning studies, in the 
sense that target coverage between the two techniques were comparable and RA OAR 
sparing was slightly improved. Although a direct comparison with other prostate 
planning studies is limited, it was also concluded that the results were of a directly 
comparable nature.           
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The now justified planning study was then applied to an independent but related 
clinical site, in an effort to both solve a clinical problem and fill a hole in the RA 
comparative literature. The clinical site in question was treatment of the prostate bed 
in the post-operative setting. This site is traditionally difficult to treat with conformal 
therapies, due to the fact that the clinical target volume resides within close proximity 
of dose limiting normal structures, combined with the techniques inability to produce 
concave dose distributions and spare said structures. As part of the presented planning 
comparison it is seen that conformal techniques are unable to treat the target volume 
without giving unacceptable doses to the rectum, and that consistently adequate 
sparing was only achieved through a significant compromise in the target volume. 
Thus, increasing the risk for a geographical miss and potentially reducing the quality 
of the treatment. This issue was alleviated through the implementation of modified 
RA planning strategies, whereby the entire patient cohort could be adequately treated 
with out compromising the target volume or over dosing the rectum. Furthermore, it 
has been shown that RA techniques give scope for significant dose escalation from 64 
to 70 Gy in the majority of patients. In saying this, care still needs to be taken not to 
over-modulate the plan or have large volumes of the rectum and PTV occupying the 
same volume of physical space.  
 
The complex nature of RA delivery is mirrored with the associated dose modeling and 
verification with much still unknown, namely, how well do current calculation 
algorithms deal with complex, irregular and often small MLC apertures. It was 
originally hypothesised that this modeling may improve if more appropriate input 
beam data was provided for the configurations of such algorithms. Namely, beam data 
that was collected with the MLC defining the field rather than the jaws. This 
hypothesis has been proven incorrect, with different input data having a negligible 
effect on the configured algorithm. Consequently it is recommended that convention 
is not broken and future configuration data be collected with the jaws defining the 
field edge. The configuration process has been seen to be very sensitive to the beam 
PDDs that are used as input data and therefore it is recommended that extra care be 
taken when these measurements are taken. Furthermore, it is recommended that 
departments with more than one linac have more than one calculation algorithm if 
their machines are now well matched in energy.  
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Since the seminal paper by Otto [6] in early 2008, delivering highly modulated 
radiotherapy treatments in a continuous arc has proven to be a time efficient 
alternative to static gantry intensity-modulated techniques. In saying this, the 
technique is still in its early stage of development with many questions still 
unanswered, including those pertinent to VMAT specifically, and IMRT in general. 
This thesis has addressed several of these questions, related to inverse planning 
techniques, dose calculation algorithms and clinical applications. 
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